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ABSTRACT 
 The incidence of type 1 diabetes (T1D) is increasing worldwide, likely due to the 
increase (or decrease, if protective) of key non-genetic factors. Though diet has been 
implicated in T1D development, its role is poorly understood, perhaps due to 
oversimplification of dietary exposures or failure to account for differences in biological 
processing of nutrients and foods. Metabolites mark response to diet, and may help 
elucidate this role when used in combination with reported intake. We examined 
combinations of dietary factors in the development of preclinical autoimmunity and 
T1D in two prospective studies: The Environmental Determinants of Diabetes in the 
Young (TEDDY) and the Diabetes Autoimmunity Study in the Young (DAISY). First, we 
identified individual metabolites and chemically similar metabolite groups associated 
with the development of multiple autoantibodies (mAb+) and T1D in metabolome-wide 
association studies. Candidate metabolites were used to capture disease-related dietary 
and nutrient patterns, which were subsequently tested for association with disease 
endpoints.  
 In TEDDY, unsaturated phosphatidylcholines, sphingomyelins, 
phosphatidylethanolamines, glucosylceramides, and phospholipid ethers in infancy 
were inversely associated with mAb+ risk, while dicarboxylic acids were associated 
with an increased risk. A dietary pattern explaining these metabolites in infancy was 
associated with decreased risk of mAb+ but was not generalizable when applied to 
similarly at-risk infants. In DAISY, a nutrient pattern explaining unknown metabolites at 
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seroconversion was associated with increased risk of progression to T1D. Nutrients 
highly contributing to this pattern included both established (linoleic acid, total sugars, 
niacin) and novel (vitamin C, riboflavin, vitamin K) dietary risk factors for T1D.   
 We made significant and novel contributions to the understanding of 
metabolomics and dietary patterns in the natural history of T1D. Our findings suggest 
that the contents of the diet may work in combination to affect the development of T1D, 
and should be considered jointly in future work. As demonstrated by this dissertation, 
expanding our methodological repertoire beyond individual risk factor epidemiology 
will improve our understanding of the disease process, and ultimately lead to more 
effective interventions to prevent, reverse, or delay development of T1D. 
The form and content of this abstract are approved. I recommend its publication. 
Approved: Jill M. Norris 
  
Everyone needs food. 
Not all bodies self-attack. 
Should you change habits? 
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 Comprehensive dietary intake measurements and analyses are paramount to 
understanding the causes of nutrition-related chronic diseases. Type 1 diabetes (T1D) 
is a chronic autoimmune disease characterized by destruction of the insulin-producing 
beta-cells of the pancreas. Incidence of T1D is increasing worldwide, suggesting that an 
essential environmental (non-genetic) factor is increasing (or decreasing, if protective) 
with time. Diet may be an important environmental factor in the development of T1D 
and its preclinical phase, islet autoimmunity (IA), which is defined by circulating 
autoantibodies. Importantly, diet is a modifiable risk factor for IA and T1D.  
 Decades of research in the appearance of IA and progression to T1D have 
identified several putative nutrients and food groups that are associated with risk. For 
example, omega-3 fatty acids have been shown to decrease risk, and cow’s milk protein 
intake increases risk. However, inconsistencies across studies suggest that focusing on 
single nutrients or foods may oversimplify the exposure. Nutrients enter the body as 
part of foods that contain other nutrients that may have synergistic or antagonistic 
effects. These nutrient intakes are so highly correlated that their effects are difficult to 
separate using traditional analytical approaches. To better understand the effects of 
diet on IA, we examined a more comprehensive picture of intake than previous studies 




 In addition to dietary intake, the biological response to what is eaten may also be 
implicated in the disease process. Once in the body, the pathways by which diet affect 
IA are not known. Ingested foods are digested, absorbed, and metabolized by the body, 
resulting in small molecules (i.e., metabolites) circulating in the bloodstream. These 
metabolites are important intermediaries because they reflect both what is ingested, 
and how it is processed by the body. Metabolites are often used as independent 
markers of dietary intake, as a solution to the inaccuracies associated with self-reported 
measures. However, metabolites can also be used to identify important biological 
pathways in disease etiology when used in conjunction with comprehensive dietary 
intake information. Previous studies have shown that changes in diet are reflected by 
changes in metabolites. Despite the important link between dietary intake and 
metabolites, no IA or T1D studies have examined them together. In order to understand 
the true effects of diet on IA, and ultimately T1D, we need new approaches to 
characterizing dietary exposure that account for complex dietary intake and 
metabolism. 
 The primary purpose of this study was to identify metabolite-related dietary 
patterns associated with IA or T1D risk. By creating dietary patterns reflective of 
important metabolites, we gained new insights into the mechanism by which diet may 
exert influence in the development of IA/T1D. While dietary pattern analyses have been 
increasingly utilized in nutritional epidemiologic studies, this was the first application 
of these methods to IA or T1D etiologic research. The study was conducted in two 
prominent ongoing T1D cohorts that both recruited children at high genetic risk of T1D 
at birth and still follow them prospectively for the development of the disease: The 
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Environmental Determinants of Diabetes in the Young (TEDDY), and the Diabetes 
Autoimmunity Study in the Young (DAISY). We accomplished the objective in three 
primary aims: 
 Identify metabolites associated with IA/T1D. 
Hypothesis 1.1: Nutrition-related metabolites are associated with development of 
IA/T1D. 
 Create dietary patterns reflective of important metabolites. 
 Test the association of dietary patterns with development of IA/T1D. 
Hypothesis 3.1: At least one dietary pattern is associated with the development of 
IA/T1D. 
 Metabolites are products of interactions among the genome, microbiome, and 
dietary intake. Using the metabolome to identify potential mechanisms by which diet 
may lead to IA can focus future etiologic research to those upstream factors in identified 
pathways. Overall, this study’s examination of the effect of combinations of metabolites 
and food was a critical next-step for the long-term goal of developing dietary 
interventions to prevent IA/T1D. 
Innovation 
The study utilized innovative approaches to estimate dietary exposure and risk 
of IA/T1D. To our knowledge, this was the first study to look at metabolite-associated 
dietary patterns in risk of IA/T1D. It was also the first in the nutrition epidemiology 
literature to examine nutrients in the identification of dietary patterns—previous 
studies have exclusively used food group intake. Combining multiple food, nutrient, and 
biomarker indicators allowed for a more complete picture of dietary exposure than 
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previous studies of IA and T1D, which have exclusively looked at individual rather than 
combinations of dietary risk factors. The use of metabolites to focus dietary patterns 
was a novel approach to “big data” studies.  
The TEDDY study is an international, multi-site consortium that provides a rich 
opportunity to examine diet and metabolomics in a pediatric population that has been 
followed closely since birth. TEDDY also offers enough power and sample size to 
answer research questions utilizing novel empirically driven statistical methods, such 
as those proposed in this project. While the DAISY study is smaller, the ability to 
implement prospective dietary pattern and metabolomics analyses in two comparable 
yet independent populations uniquely positioned us to conduct the proposed 
innovative research.  Figure I-1 summarizes the prospective follow-up of children in 
the TEDDY and DAISY studies, and an overview of the identification of dietary patterns 
and metabolomics in the development of IA/T1D. 
Figure I-1: Dissertation introduction. The prospective TEDDY and DAISY cohorts 
follow children for the development of islet autoimmunity (IA) and type 1 diabetes 
(T1D). We identified dietary patterns and metabolomics that were associated with the 
development of IA in the TEDDY study, and nutrient patterns and metabolomics that 





Natural History of Type 1 Diabetes 
T1D is a chronic, immune-mediated disease characterized by the destruction of 
the insulin-producing beta-cells of the pancreas by autoreactive T-cells.1 Development 
of these islet reactive autoantibodies is thought to be induced after a genetically-
susceptible individual is exposed to some putative environmental risk factor that 
triggers a loss of immune regulation.2 Destruction of the beta-cells leads to a decrease in 
insulin secretion, the development of hyperglycemia, and ultimately T1D diagnosis. 
Preclinical Markers 
T1D is preceded by IA, a preclinical, asymptomatic phase in which 
autoantibodies to beta-cell antigens are detectable in serum.3 Four autoantibodies are 
considered biomarkers for IA, including insulin,4 GAD,5 IA-2,6 and zinc transporter.7 
Seroconversion to IA-positivity occurs when one of the four autoantibodies are 
persistently detectable by immunoassay, typically no earlier than 3 months of age and 
by 2-4 years of age for the majority of people who progress on to T1D.8–10  
The autoimmune process preceding T1D is heterogeneous—the type and 
number of first-appearing autoantibodies distinguish subgroups with shared 
characteristics in the disease process.11 For example, while incidence of any IA peaks at 
2 years of age, the incidence of insulin as the first-appearing autoantibody (IAA) peaks 
at age 1-year and rapidly declines while incidence of GAD as the first-appearing 
autoantibody (GADA) appears later with steadier incidence.12,13  Other genetic and 
environmental factors, such as human leukocyte antigen (HLA) genotype, SNPs in 
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PTPN22, ERBB3, INS, and BACH2 genes, age-at first-appearing autoantibody, male sex, 
and father as the diabetic proband may distinguish autoimmune phenotypes and the 
risk for developing a second autoantibody and/or T1D.12 A study pooling data from 
three prominent T1D cohorts showed that 70% of children with multiple autoantibody 
positivity (mAb+, or stage 1 T1D) progressed on to T1D within 10 years of 
seroconversion, and the progression was faster for 1) children who seroconverted at 
less than 3 years of age compared to those 3 years and older, 2) children with the high-
risk HLA DR3/DR4 genotype compared to other HLA genotypes, and 3) girls compared 
to boys.14 
Genotype is another marker used to identify at-risk populations, and is used to 
recruit patients into most T1D etiologic studies. The Type 1 Diabetes Genetic 
Consortium was an international, multi-site collaborative that made major 
contributions to the understanding of genetic risk predictors for T1D,15 including the 
identification of over 40 genetic loci associated with T1D risk.16 The HLA region on 
chromosome 6 accounts for over 50% of the genetic risk for the disease, with some HLA 
class II haplotypes increasing disease risk (i.e., DRB1*0301-DQA1*0501-DQB1*0201, 
DRB1*0405-DQA1*0301-DQB1*0302), and some haplotypes decreasing risk (i.e., 
DRB1*1501-DQA1*0102-DQB1*0602, DRB1*1401-DQA1*0101-DQB1*0503).17  However, 
the frequency of high-risk HLA genotypes among T1D cases has decreased over time, 
indicating that genetic predisposition is less predictive than in the past.18,19  
Diagnosis and Treatment 
 T1D diagnoses occurs in stages, following guidelines set forth by the American 
Diabetes Association.20 Given the high probability of progression to T1D once multiple 
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autoantibodies are detectable, Stage 1 of T1D is characterized by multiple autoantibody 
positivity, normoglycemia, and is generally presymptomatic. Patients with multiple 
autoantibody positivity and no clinical symptoms progress to Stage 2 T1D when 
dysglycemia begins, as measured by impaired fasting glucose or impaired glucose 
tolerance. Further onset of hyperglycemia and clinical symptoms indicates Stage 3 T1D, 
diagnosed by standard criteria where fasting blood glucose is higher than 7 mmol/L 
(126 mg/dL), 2-hour blood glucose is 11.1 mmol/L (200 mg/dL) or higher, symptoms 
of hyperglycemia accompanied by any blood glucose test is 11.1 mmol/L (200 mg/dL) 
or higher, or glycated hemoglobin (HbA1c) test is 48 mmol/mol (6.5%) or higher.  
After disease onset, T1D cases are treated with exogenous insulin for the 
remainder of their lives. Modern technological advances have improved treatment of 
T1D and development of complications through the use of devices that better monitor 
and regulate insulin and blood glucose levels (i.e., insulin pump, continuous glucose 
monitor, artificial pancreas device system), and by improved insulin preparations (i.e., 
long-acting versus rapid-acting insulin).21 The Diabetes Complications and Control Trial 
(DCCT), which began in 1983, showed that intensive treatment aimed at keeping blood 
glucose close to normal levels was more effective at reducing diabetic-induced eye, 
kidney, and nerve damage than the standard treatment aimed at avoiding symptomatic 
hyper- or hypoglycemia.22 These results changed the standard of clinical care for T1D 
patients. However, much of this progress is limited to the developed-world, as vast 





Prognosis and Complications 
While T1D has been associated historically with increased risk of early 
mortality,23,24 survival has improved over the last 80 years, especially in high-income 
countries. Successes in insulin availability and treatment have led to increased life-
expectancy and decreased mortality among those diagnosed in childhood. The 
Pittsburgh Epidemiology of Diabetes Complications study found that children 
diagnosed with T1D from 1965 to 1980 were expected to live 68.8 years at birth, almost 
15 years longer than those diagnosed between 1950 and 1964, and only 3.6 years less 
than the general population.25 From 2008-2009 to 1968-1969, the CDC diabetes death 
rate decreased 68% among US children less than 20 years of age (to 1.05 per million 
persons), and 78% among US children less than 10 years old.26 In contrast, life-
expectancy is seen as low as 0.6 years among children under 15 years of age diagnosed 
with T1D in low- and middle-income countries.27  Limited access to trained healthcare 
professionals, diagnostic tools, and insulin likely contribute to these disparities.28,29 
T1D often leads to kidney and cardiovascular complications, which are the 
primary causes of early mortality.30 The observational follow-up study of 90% of DCCT 
participants, called the Epidemiology of Diabetes Interventions and Complications, 
showed that the intensive treatment received during the trial had long-term benefits, 
reducing the development of renal disease,22,31 cardiovascular disease,32 and all-cause 
mortality33 among T1D patients. In the absence of renal disease, the 20-year mortality 
risk for T1D patients diagnosed in childhood is now comparable to the nondiabetic 
population.34 While these improvements in T1D management, treatment and care have 
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led to successes in life-expectancy and mortality in those living with T1D, effective 
primary and secondary prevention strategies remain unclear. 
Primary and Secondary Prevention 
 Given the likely role of environmental factors in disease pathogenesis, the early 
age at IA onset, and the high likelihood that children with IA will progress on to T1D, 
the few primary prevention trials have focused on early life dietary modifications to 
prevent IA. The Trial to Reduce IDDM in the Genetically at Risk showed that hydrolyzed 
infant formula was not associated with IA or T1D compared to cow’s milk formula, 
among genetically at risk children who did not have breast milk available.35,36 While 
dietary interventions for primary prevention have not yet been successful, participation 
and compliance in the trial indicates that a large-scale dietary intervention in young 
children is feasible.  
Secondary prevention trials to prevent or delay the progression to T1D among 
those with IA have been largely unsuccessful. Neither oral insulin,37 nicotinamide,38 nor 
intranasal insulin39 have been very effective at preventing or delaying diabetes onset. 
Reversal or halting of beta-cell destruction after T1D onset is not yet possible, though 
alternative treatments to exogenous insulin therapy, such as islet-cell transplantation, 
show promise.40 Development of successful prevention strategies have been hindered 
by the inability to identify environmental risk factors unequivocally associated with 
disease, but are important to develop given the increasing presence of T1D worldwide.  
Population-based screening for the high-risk multiple autoantibody positive 
children, whose lifetime risk of symptomatic (Stage 3) T1D approaches 100%,14  has 
been initiated by the Fr1da Study in Germany41 and the Autoimmunity Screening in 
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Kids (ASK) in the United States.42  Earlier detection of Stage 1 T1D may reduce costly 
morbidities at symptom onset and improve longer-term diabetic control.43–45 The 
identification of these high-risk populations also enhances the ability to conduct trials, 
and will allow for faster implementation of effective interventions to prevent or delay 
the progression from Stage 1 to Stage 3 T1D.  
Epidemiology of Type 1 Diabetes 
T1D affects approximately 40 million people worldwide,28 including 1.4 million 
Americans.46 Over 542,000 children are affected, making it the most common chronic 
disease in children.28 The WHO DIAMOND project estimated T1D incidence in the 1990s 
to range from over 40 per 100,000 persons per year (in Finland) to less than 1 per 
100,000 persons per year (in Venezuela) using in-country diabetes registries. Since 
then, global incidence of T1D has been increasing, especially in central and eastern 
European countries and among children less than 5 years of age.47 The rate of increase 
in incidence is estimated between 3-4% annually in European children less than 15 
years of age,48 and 2.7% annually in the US among children less than 20 years of age.49 
Recent reports from Finland,50 which has the highest incidence rate of T1D in the world 
at more than 60 per 100,000 persons per year,51 and Sweden52 indicate that the rate of 
increase among children is beginning to plateau, though some question the validity of 
those conclusions due to short periods of categorization used in time trend analyses.53 
Furthermore, T1D is often misclassified as type 2 diabetes, particularly in adults, likely 
leading to a gross underestimate of the true incidence of T1D.54  
Age at T1D onset and sex differences in incidence vary geographically. Incidence 
rates tend to be higher in higher income countries and lower in African and other 
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developing nations, though incidence data are sparse in many low income countries.47 
While T1D can develop at any age, the incidence in European countries is higher in 
children aged 0-14 years than in young adults aged 15 to 29 years.55 T1D diagnoses 
tend to peak between 5-7 years of age and again near puberty in these populations.56 In 
contrast, peak incidence in the few African nations with available data occurs in young 
adults aged 15 to 29 years.57–59 Differences in T1D incidence by sex are slight, unlike 
most other autoimmune diseases. Males tends to have a slight excess in high-incidence 
countries, whereas females tend to have a slight excess in low-incidence countries.60 
These geographic differences in the epidemiology of T1D may be explained by 
differences in detection or heterogeneity in exposure to environmental disease triggers. 
T1D incidence also displays seasonal patterns. More cases of T1D are diagnosed 
in the autumn and winter months, and fewer in the summer, regardless of age, sex, 
hours of sunshine, and average temperature.61,62 Being born in the spring is also 
associated with an increased risk of T1D among U.S. youth, which may relate to sunlight 
exposure in either the prenatal or postnatal environment.63 Heterogeneity in T1D 
incidence over time, geography, age, and season all support a theoretical role for 
environmental factors in driving its development. Furthermore, by age 60 years, only 
65% of monozygotic twins are concordant for T1D status,64–66 implicating 
environmental factors in disease etiology. 
Though genetics explain the majority of risk for T1D, genetic changes cannot 
account for the rapid increases in T1D incidence.67 Geographic, seasonal, and age 
differences in the incidence of T1D, combined with the lessening contribution of genetic 
factors, suggest environmental (non-genetic) influences are important.68 Given the 
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peaks in IA incidence during infancy and adolescence, diet has been implicated as an 
environmental risk factor that triggers development of T1D on top of a background of 
higher genetic risk.  
While in utero exposures69–71 and the timing of food introduction in the infant 
diet72–75 may make early contributions to the development of disease, childhood dietary 
intake is an important ongoing exposure. New results in children at high-genetic risk for 
T1D suggest that later introduction of gluten-containing cereals may increase the risk 
for IA, but the timing of introduction of other solid foods do not show a clear 
association.76 Decades of research have identified several dietary factors that are 
associated with IA or T1D (Table II-1). Cow’s milk protein77,78, omega-3 fatty acids79–81, 
glycemic index82, and sugar83 have been shown to be associated with either IA or T1D, 
while soluble fiber84 and omega-6 fatty acids79 have not been. Other dietary factors, 
such as vitamin D intake, may influence risk of IA or T1D, but only among subgroups 
with specific genotypes.85,86  However, results are inconsistent across studies,87 and no 
particular dietary agent has yet been confirmed in T1D pathogenesis.68 Difficulties with 
dietary analytical approaches and exposure assessment may explain some of the 
inconsistency in T1D nutritional epidemiology research, and can be addressed by using 
metabolomics and dietary patterns. 
Metabolomics and Dietary Intake in the Development of IA and T1D 
Small molecules present in biological fluids (blood, saliva, urine), or metabolites, 
are increasingly studied as alternative markers of nutrition or disease status. 
Metabolites are products of interactions among the genome, microbiome, and dietary 
intake,89 and are reflective of many factors related to human health.90 Biomarker 
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discovery often focuses on identifying a single marker that represents a particular food 
group; however, a combination of metabolites may be a more accurate measure of 
dietary exposure or disease status.91 Metabolites have been used in conjunction with 
dietary patterns to identify changes reflective of reported nutrition,92 new biomarkers 
of foods or nutrients,93 and biological pathways important for disease progression.94 
The few small IA and/or T1D studies that have explored metabolomics have identified 
serum methionine,95 triglycerides,95,96 antioxidant phospholipids,96,97 and amino 
acids95–97 as important predictors (Table II-2). Interpreted independently, these 
findings are inconclusive as these metabolites could reflect immune, genetic, dietary, or 
other biological changes.98 Metabolites discovered in the context of dietary intake, on 
the other hand, are more interpretable, and their combined use has been shown to 
reduce bias and increase statistical power to detect diet-disease relationships.99,100 
 
Table II-1: Previously studied dietary risk factors for IA/T1D. 
Food or nutrient Associated with IA or T1D 
Direction of 
increased 
intake on risk 
Reference Cow’s milk protein IA*; T1D ;  77,78 Omega-3 fatty acids IA  80 Fruit and berry juices IA  78 Sugar T1D  83 Soluble fiber Neither  84 Omega-6 fatty acids Neither  79,80 Vitamin D Neither  85 Gluten Neither  88 
 
 
*only for subjects with low risk HLA genotypes 
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Table II-2: Previously studied metabolomics risk factors for IA/T1D. 




Reference Methionine IA * 95 Amino acids T1D  96,97 Triacylglycerols (TG) IA; T1D *;  95,96 Phosphatidylcholines (PC) T1D; young T1D; IA; T1D ; ; ;  95–97,101–103 Ether phospholipids (ether PL) T1D  96 Sphingomyelins (SM) T1D; not IA  101,103 Phosphatidylethanolamines (PE) Young T1D  102 Polar metabolites (full panel) IA None 104 
 
 
Traditional investigation of diet and disease examines the effects of individual 
nutrients or foods, and does not account for the complexity of the diet—the effects of 
single nutrients and foods are often too small to identify, or too highly correlated to 
separate.100 Newer methods that overcome the challenges of examining diet 
comprehensively are increasingly used to identify dietary patterns that integrate both 
food intake and biomarker status.105–107 Dietary patterns represent a more complete 
picture of diet and are more strongly associated with disease than single nutrients or 
food.108 For example, dietary patterns have been particularly useful in research on 
cardiovascular disease (CVD), where a Mediterranean diet pattern was consistently 
identified as protective in observational studies and intervention trials.109 Dietary 
patterns offer a solution for examining whole-diet effects in the development of disease.  
*early seroconverters (<2 years) compared to late seroconverters (>=8 years) 
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Comprehensive dietary intake measurement and analysis are paramount to 
understanding the causes of nutrition-related chronic diseases, such as T1D. Incidence 
of T1D is increasing worldwide, suggesting that an essential environmental (non-
genetic) factor is increasing (or decreasing, if protective) with time. Diet may be an 
important, modifiable risk factor in the development of IA or T1D. Decades of research 
in the role of diet in the appearance of IA and progression to T1D have identified 
several putative nutrients and food groups that are associated with risk. For example, 
omega-3 fatty acids have been shown to decrease risk, and cow’s milk protein intake 
increases risk. However, inconsistencies across studies suggest that focusing on single 
nutrients or foods may oversimplify the exposure (Figure II-1). Nutrients enter the 
body as part of foods that contain other nutrients that may have synergistic or 
antagonistic effects. These nutrient intakes are so highly correlated that their effects are 
difficult to separate using traditional analytical approaches. To better understand the 
effects of diet on IA, we will examine a more comprehensive picture of intake than 
previous studies using a summary measure of foods or nutrients eaten in combination, 
or a dietary pattern. 
In addition to dietary intake, the biological response to what is eaten may also be 
implicated in the disease process. Once in the body, the pathways by which diet affect 
IA are not known. Ingested foods are digested, absorbed, and metabolized by the body, 
resulting in small molecules (i.e., metabolites) circulating in the bloodstream. These 
metabolites are important intermediaries because they reflect both what is ingested, 
and how it is processed by the body. Metabolites are often used as independent 
markers of dietary intake, as a solution to the inaccuracies associated with self-reported 
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measures. However, metabolites can also be used to identify important biological 
pathways in disease etiology when used in conjunction with comprehensive dietary 
intake information. Previous studies have shown that changes in diet are reflected by 
changes in metabolites. Despite the important link between dietary intake and 
metabolites, no IA or T1D studies have examined them together. In order to understand 
the true effects of diet on IA, and ultimately T1D, we need new approaches to 




Figure II-1: Complexities in correlation of dietary intake exposures. a) Previous 
studies of dietary intake in IA/T1D oversimplify dietary exposures by considering only 
individual foods or nutrients, when in reality dietary intake is highly correlated. b) 
Nutrient and food intake effects are also highly correlated and their effects difficult to 
separate with traditional analytical approaches. 
 
The overall objective of this dissertation is to identify metabolite-related dietary 
patterns associated with IA risk. We will accomplish this objective in three distinct 
scientific aims: 1) identify metabolites associated with IA/T1D, 2) create dietary 
patterns reflective of important metabolites, and 3) test the association of dietary 
patterns with development of IA/T1D (Figure II-2). By creating dietary patterns 
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reflective of important metabolites, we will gain new insights into the mechanism by 
which diet may exert influence in the development of IA or T1D. While dietary pattern 
analyses have been increasingly utilized in nutritional epidemiologic studies, this will 
be the first application of these methods to IA or T1D etiologic research. The study will 
be conducted in two prominent ongoing T1D cohorts that both recruited children at 
high genetic risk of T1D at birth, and follow them prospectively for development of the 
disease: The Environmental Determinants of Diabetes in the Young (TEDDY) study, and 
the Diabetes Autoimmunity Study in the Young (DAISY). TEDDY is a multi-center 
consortium that began following 8,676 newborn infants at high-genetic risk for T1D in 
the US, Germany, Sweden, and Finland in 2004.110 DAISY has followed 2,547 children at 
high-genetic risk for T1D in Colorado for development of IA and further progression to 




Figure II-2: Dissertation organization. a) This dissertation accomplished three aims 
in two prospective studies of T1D: The Environmental Determinants of Diabetes in the 
Young (TEDDY) and the Diabetes Autoimmunity Study in the Young (DAISY). b) 






To achieve our goal of elucidating more of the nutrition etiology of IA/T1D by 
identifying combinations of metabolites and foods that affect IA or T1D risk, we first 
test metabolites for risk of disease (Aim 1). Then we will identify dietary intake 
patterns that best explain the variation in those important metabolite candidates (Aim 
2). Finally, we will apply those dietary patterns longitudinally to test their association 
with the development of IA or T1D (Aim 3). All aims were conducted independently in 
the TEDDY and DAISY studies, with alterations to the methods as appropriate for each study’s design (Table III-1). This shift to combinations of dietary factors, rather than a 
reductionist one-at-a-time approach, may help clarify the inconsistencies in the role of 
diet in development of IA and T1D. Results from a dietary intake-level exploration that 
is focused by biologically meaningful metabolites are more interpretable than previous 
approaches and will highlight important biological mechanisms on the pathway from 
dietary intake to IA and T1D. Comparison of the measures available in both studies are 
described below (Table III-2). 
Table III-1: Summary of approach by Aim and study. 





TEDDY Nested case-control Metabolite or lipid IA, mAb+ Conditional logistic regression 
DAISY Cohort Metabolite or lipid T1D Cox regression 
Aim 2 
TEDDY Cross-sectional Foods Metabolites Reduced rank regression 
DAISY Cross-sectional Nutrients Metabolites Reduced rank regression 
Aim 3 
TEDDY Cohort Dietary pattern mAb+ Cox regression 
DAISY Cohort Nutrient pattern T1D Cox regression 
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Table III-2: Availability of relevant measures in TEDDY and DAISY. 
 
Study Designs, Populations, and Measures 
TEDDY Study 
From 2004-2010, TEDDY screened and enrolled 8,676 newborn infants with a 
high- or moderate-risk HLA genotype at six locations around the world: 
Georgia/Florida, Colorado, and Washington (in the USA), and Finland, Sweden, and 
Germany.110 Dietary assessment is carried out by 24-hour recall at the first clinic visit at 
3 months of age, then by 3-day food record every 3 months until 12 months of age, and 
then every 6 months thereafter until follow up stops at age 15 years.112 The foods 
consumed were quantified into food groups (e.g., cereals, fruits and berries, etc.) and 
subgroups (e.g., wheat, rice, oats, citrus fruits, apple, berries, etc.). From quantities of 
foods consumed, the amount of nutrients contained therein were then quantified using 
national food composition databases unique to each country. Results of a detailed 
nutrient harmonization study documented 21 nutrients that were comparable across 
study centers, despite potential differences in food composition databases.112 Results 
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from food group harmonization indicated 15 main food groups, and 89 subgroups were 
comparable among TEDDY study centers.113 
Blood samples were collected on TEDDY participants every 3 months until 4 
years of age, and biannually thereafter until age 15 (Table III-2).114 A nested case-
control study was conducted in TEDDY to reduce the amount of resources needed to 
assay samples for metabolomics and other measures. A case of IA was defined as the 
presence of an autoantibody (GAD65A, IA-2A or IAA) at two or more consecutive visits. 
Risk set sampling115 was used to match 418 cases of confirmed persistent IA to 1253 
controls (matched 1:3) who were autoantibody free at the time of the case’s IA 
seroconversion visit, based on clinical center, sex, and family history of T1D.116 At the 
time of selection in May 2012, the mean age of the cases was 24 months, 23% had a first 
degree relative with T1D, and 44% were female.116 Untargeted primary metabolism and 
complex lipid panels were run at The NIH West Coast Metabolomics Center, University 
of California Davis, CA, USA on 9,394 plasma samples from every available time point 
prior to the time of IA seroconversion in cases and controls.116  
DAISY Study 
From 1993-2004 DAISY screened and enrolled 2,547 children in Colorado with 
high-risk HLA genotype or a first-degree relative with T1D, 1,886 of whom entered the 
study prior to age 15 months.73 Prospective dietary assessment was collected via a food 
frequency questionnaire (FFQ) completed by the parent beginning when the child was 2 
years old concerning the diet in the previous year, and continuing annually until age 10, 
when the subjects were asked to self-report diet using a youth adolescent questionnaire 
(YAQ). Data collected by FFQ and YAQ dietary assessment tools have been shown 
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comparable if an indicator is used designating the assessment tool.117 The FFQ has been 
validated in the DAISY population using multiple 24-hour recalls and biomarkers.118,119  
Blood samples were collected on DAISY participants at age 9, 15, and 24 months, 
and annually thereafter. A nested case-control study was conducted in DAISY using a 
similar case definition as in TEDDY, where a case of confirmed persistent IA was 
defined as the presence of one confirmed autoantibody (GAD65A, IA-2A IAA, or ZnT8) 
on two or more consecutive visits. Cases were frequency matched to controls by age, 
ethnicity, and sample availability for important time points of interest—e.g., birth, early 
visit (9 or 15 months of age), the visit prior to conversion to IA, the IA visit, and the visit 
just prior to T1D diagnosis (Figure III-1). Upon selection in 2015, the mean age of the 
cases was 12.9 years, 48% were female, and 79% were non-Hispanic white.  Like in 
TEDDY, untargeted primary metabolism and complex lipid panels were run at The NIH 
West Coast Metabolomics Center, University of California Davis, CA, USA.  
 
Figure III-1: DAISY nested case-control study design. 
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Specific Aim 1: Identify Metabolites Associated With IA/T1D 
Metabolite Quantification and Pre-Processing 
Led by dissertation committee member Dr. Oliver Fiehn at The NIH West Coast 
Metabolomics Center, University of California Davis, CA, USA, TEDDY measured 
metabolites on the 9,394 plasma samples in the nested case-control study. Two 
platforms were utilized: 1) CSH-QTOF MS platform which quantifies more than 350 
lipids covering 12 lipid classes, and 2) GC-TOF MS platform which quantifies up to 170 
primary metabolites such as amino acids, sugars, and hydroxyl acids. Initial data 
processing was completed at UC Davis and included locally estimated scatterplot 
smoothing (LOESS)120 normalization to internal standards and adjustment for batch or 
series effects. After laboratory pre-processing, TEDDY received measurements on 364 
metabolites from the GC-TOF platform and 816 lipids from the CSH-QTOF platform. 
These data became available on the TEDDY online data sharing platform in December 
2016. 
DAISY metabolomics were similarly acquired from the NIH West coast 
Metabolomics Center, using the GC-TOF platform for primary metabolites and the CSH-
QTOF for lipids. An additional panel of data was acquired in DAISY, covering biogenic 
amines using HILIC-QTOF-MS. There were 734 DAISY visits selected for the nested 
case-control study with sufficient sample available for metabolomics, resulting in 2,720 
metabolite features received from all 3 platforms.  Table III-3 summarizes the number 




Table III-3: Summary of the number of untargeted metabolites received from The 
NIH West Coast Metabolomics Center by panel and study. 







HILIC QTOF-MS  
(biogenic amines) 
NA 1,176 





We conducted a metabolome-wide association study (MWAS) on the subset of 
children in the TEDDY cohort selected for the biomarker nested case-control study. 
Primary metabolomics analyses were conducted at the first of two consecutive clinic 
visit positive for autoantibodies (seroconversion, SV), just prior to development of IA 
(pre-seroconversion, PSV), and prior to the detection of autoantibodies at 9-months 
(infancy). Conditional logistic regression was used to examine the association between 
each metabolite (including unknowns) and being a case, controlling the false discovery 
rate (FDR) using the Benjamini-Hochberg multiple comparisons correction.121 Models 
were adjusted for matching factors (clinical center, sex, and family history of T1D), HLA 
genotypes, and age. We considered several outcomes, including: persistent confirmed 
positivity to any autoantibody (IA), or to insulin only (IAA), GAD only (GADA), or IA2 
only (IA-2A) at IA event time. IA-2A was ultimately excluded as an outcome since very 
few cases developed IA2 as their first and only persistent confirmed autoantibody at IA 
case-time. Multiple autoantibody positivity (mAb+) was defined as any subject positive 
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for more than one autoantibody at IA event time, or who developed more than one 
autoantibody during follow-up. 
To better understand the relationship between nominally significant annotated 
metabolites, and to account for the correlation between metabolites, results from the 
TEDDY MWAS were used to conduct enrichment analysis using the ChemRICH tool.122 
Key metabolites identified from significant (p<0.05) chemically similar groups were 
used for dietary pattern analyses in Aim 2.  
We also conducted a MWAS in DAISY to identify seroconversion metabolomics 
associated with progression from IA to T1D. The 213 IA cases selected for the DAISY –
omics nested case-control study were eligible to have metabolomics, which represents 
all IA and T1D cases identified in DAISY as of January 2015. All metabolites were 
included in analyses, including those quantified from the panels used in TEDDY 
(primary metabolites, complex lipids), and the new panel of biogenic amines. Primary 
analyses were conducted using Cox regression to model the hazard of metabolite level 
at seroconversion and time to T1D diagnosis event, adjusting for age at seroconversion 
and HLA genotype. Both annotated and unknown significant metabolites were retained 
for the creation of dietary patterns in DAISY.  
Expected Outcomes and Power 
We hypothesized that both annotated, nutrition-related metabolites and 
unknown metabolites would be associated with IA and T1D outcomes after FDR 
correction. Though not named, unknown metabolites were uniquely indicated in the 
Fiehn laboratory database, and could therefore be interrogated for function, identity, 
and occurrences in other studies. Significant unknown metabolites were evaluated 
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using the laboratory’s in-house BinVestigate tool. BinVestigate looks for the unknown 
compound in the Fiehn laboratory database containing 1,850 metabolomics studies 
representing 90,000 processed samples, and reports similar characteristics of the 
unknown across studies, including tissue type analyzed (stool, plasma, etc.) and 
outcome evaluated against.  
The TEDDY nested case–control study selected 418 cases and 1253 controls, but 
the number of pairs for metabolomics analyses was reduced to 1002 due to sample 
availability. The study had 80% or greater power at a significance level of 5% to detect ≥2.01 relative risk (RR) with 1002 pairs if the proportion of exposure was 5%.116 
Bonferroni adjustment for ~1,000 tests (alpha = 0.00005) will allow us to detect RR ≥ 
2.92. DAISY had 80% or greater power at a significance level of 5% to detect ≥ 2.61 RR 
with 213 pairs if the proportion of exposure was 5%. Correcting for Bonferroni 
adjustment for 1,000 tests, DAISY had power to detect ≥ 4.12 RR. All power analyses 
were conducted using SAS® software version 9.4.  
Specific Aim 2: Create Dietary Patterns Reflective of Important Metabolites 
Statistical Analysis 
Dietary patterns were identified in both studies using reduced rank regression 
(RRR). RRR is a statistical method that uses linear combinations of predictors to explain 
the maximum covariance of a set of response variables.123 For creating dietary patterns 
that are relevant for IA outcomes in TEDDY, food group intake was used as predictors to 
explain metabolites (response variables) that were identified from Aim 1 as 
significantly associated with development of IA outcomes in TEDDY. All food subgroups 
that were shown to be comparable across countries based on the TEDDY food 
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harmonization study, and survived the pre-processing pipeline were used in the 
analysis. Food groups were standardized to the full 9-month TEDDY population for RRR 
analyses. Metabolites were standardized by all metabolomics in the TEDDY nested case-
control study. 
We conducted a similar RRR analysis in DAISY to create nutrient patterns of 
intake that explained the most variation in the significant metabolites identified in Aim 
1 in DAISY. Metabolites were used as RRR response variables. Due to smaller sample 
size in DAISY, nutrients used as predictor variables in RRR were selected after a multi-
step filtering process. First, only nutrients consistently obtained from questionnaires 
over the entire course of the DAISY study were considered for inclusion in nutrient 
pattern analysis (n=38). Then, using stepwise selection, only nutrients that were 
significant predictors (p<0.1) for at least 2 of the metabolite response variables were 
included in RRR. Nutrients and metabolites were standardized to the 132 IA cases with 
both measures at seroconversion.  
All RRR analyses were conducted using SAS® software version 9.4. In RRR 
analysis, the maximum number of dietary patterns identified, or the rank of the RRR 
model, is equal to the number of response variables included. The number of dietary or 
nutrient patterns needed to best explain the variation in metabolites was chosen by the 
van der Voet T2 statistic, which indicates the least number of extracted factors whose 
residuals are not significantly greater than those of the model with minimum error.124 
Alternately, the number of dietary/nutrient patterns can be chosen by minimizing the 
predicted residual sum of squares (PRESS). The factors, or dietary/nutrient patterns, 
created as output of the RRR procedure consist of relative weights, called factor 
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loadings, given to food groups or nutrients. The factor loadings of food groups/nutrient 
on each dietary/nutrient pattern and the partial correlation with metabolite response 
variables were used to interpret each pattern. The goodness-of-fit of the 
dietary/nutrient patterns was evaluated by examining the percentage of metabolite 
variation explained overall and by each pattern. 
Expected Outcomes and Power 
This aim produced the factor structure and description of dietary patterns that 
explain variation in IA-associated metabolites (TEDDY), and nutrient patterns that 
explained variation in T1D-associated metabolites (DAISY). We hypothesized that RRR 
analyses would identify at least one metabolite-related dietary pattern in TEDDY and at 
least one metabolite-related nutrient pattern in DAISY. We expected the total amount of 
metabolite variation explained by the patterns to range from 3-8%, typical of other RRR 
analyses using biomarkers or metabolites as response variables and dietary intake as 
predictor variables.107,125,126 Factors loadings for food groups or nutrients on the 
pattern were also expected to fall within previous published ranges, generally less than 
0.4.127,128  
Power calculations for RRR depend on the degrees of freedom in the model. 
Unlike other covariance modeling strategies, such as principal components regression 
or structural equation modeling, RRR degrees of freedom depend on the response 
variable matrix, and methods to calculate them are still in development.129 However, 
compared to other studies successfully using RRR, such as European Prospective 
Investigation into Cancer and Nutrition (EPIC) (n=402 to 2,267),123,125 Western 
Australian Pregnancy (Raine) Cohort Study (n=783),130 Framingham Offspring Study 
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(n=2879),131 and UK Avon Longitudinal Study of Parents and Children (ALSPAC) 
(n=6106 to 7285),132 we have comparable sample size of 1,002 pairs in the TEDDY 
study. Though we are much less powered in the DAISY study, the filtering of predictor 
nutrients for inclusion in RRR improved our ability to identify metabolite-related 
nutrient patterns.133    
Specific Aim 3: Test the Association of Dietary Patterns with Development of 
IA/T1D 
Statistical Analysis 
Reported food group intake for each TEDDY participant was scored by the RRR 
procedure based on each pattern identified in Aim 2. The score for each pattern 
represented how similar their dietary intake was to the dietary pattern. Multiple 
dietary patterns were produced as a result of the RRR procedure, and could be 
subsequently modeled together because they were statistically independent.  
Dietary pattern scores were first tested in the nested case-control study using 
conditional logistic regression to account for matching strata, and adjusted for high-risk 
HLA genotype and age at blood draw. Then we used Cox regression to test the 
association of the dietary pattern score in infancy for the full TEDDY cohort with risk of 
mAb+ adjusting for clinical center, high-risk HLA genotype, family history of type 1 
diabetes, total energy intake, and sex. Time-to-event analyses were performed to 
evaluate whether metabolite-related dietary pattern scores were associated with mAb+. 
Cases included those selected for the nested case-control study plus any additional 
cases that developed in TEDDY by January 2018.  
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In DAISY, subjects received a score reflecting how similar their nutrient intake at 
seroconversion was to the nutrient pattern, using the RRR procedure. The association 
of the nutrient pattern score and progression to T1D was tested using Cox regression 
models adjusted for age at seroconversion and high-risk HLA genotype. 
Expected Outcomes and Power 
Given that the dietary and nutrient patterns explain variation in outcome-related 
metabolites, we hypothesized that any patterns identified in Aim 2 would be associated 
with outcomes in Aim 3. The direction of association is expected to be consistent with 
the hypothesized direction of dietary factors loading highly onto the pattern. For 
example, a dietary pattern characterized by intake high in foods containing omega-3 
fatty acids (which is thought to be protective for IA or T1D risk)80 would be inversely 
associated with IA or T1D risk.  
Using Cox proportional hazards, a two-sided log rank test in a sample size of 
8,676 TEDDY subjects with an overall IA rate of 9% in 5 years achieves 80% power at a 
0.05 significance level to detect a hazard ratio (HR) > 1.23 assuming the proportion of 
children lost to follow-up is 20% (Table III-4). In a similar Cox proportional hazards 
framework, a two-sided log rank test in a sample size of 213 DAISY IA cases with an 
overall T1D rate of 40% in 5 years achieves 80% power at a 0.05 significance level to 
detect a hazard ratio (HR) > 1.75 assuming the proportion of children lost to follow-up 
is 20%. HRs are based on a one standard deviation change in dietary or nutrient pattern 
score. We have good power to detect dietary pattern associations with IA in TEDDY, and 




Table III-4: Detectable HR with various power for Aim 3. 
 
Potential Pitfalls and Alternative Approaches 
Given the exploratory nature of our Aims, and the unique strength of having 
access to two similarly conducted prospective studies of T1D, there were many 
alternative approaches considered for identifying combination of dietary factors 
associated with IA and T1D outcomes. Ultimately, we selected the most statistically 
sound and interpretable approaches to account for the complex nature (high-
dimensional, correlated) of metabolomics and dietary intake, and the two different 
nested study designs.  
Alternative statistical frameworks commonly used for metabolomics analyses 
were considered, but ultimately deemed inappropriate due to the longitudinal, matched 
study design with multiple adjustment factors. Unsupervised models used for high-
dimensional data, such as principal components analysis (PCA)134, K-means 
clustering135, and self-organizing maps (SOM)136, are useful for exploration and 
visualization of metabolomics data that might inform further statistical analyses. 
However, they cannot account for the correlation of repeated measures on study 
subjects, do not perform hypothesis testing, and cannot incorporate an adjustment for 
confounding factors. While components identified in PCA can be applied longitudinally 
 TEDDY* (n=8,676) DAISY** (n=213) 
Power HR HR 
70% 1.2 1.65 
80% 1.23 1.75 
90% 1.26 1.90 
*Assuming 9% IA rate and 20% loss to follow-up in 5 years 
**Assuming 40% T1D rate and 20% loss to follow-up in 5 years 
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to repeated measures as a reduced, composite measure of metabolite exposure, the 
components summarizing the most variability in the data (the first ones, which are 
typically used in this manner) may not reflect disease-causing metabolites. Supervised 
learning methods, such as partial least squares (PLS, PLS-DA)137, identify metabolites 
that discriminate between outcomes (case versus control), however it is difficult to 
incorporate confounding variables and to account for the matching strata. Selecting 
cross-sections of interest in the natural history of T1D allowed us to account for 
matching strata from the matched case-control design in TEDDY and to adjust for 
confounding factors in both studies.  
Principal components analysis (PCA), partial least squares, cluster analysis, and 
RRR are all common dimension reduction methods for combining multiple food or 
nutrient exposures in a way that accounts for their complex correlation. Multiple 
studies assessing differences in the methods as applied to nutrition studies conclude 
that RRR is most appropriate for investigating disease etiology or pathophysiology, as it 
incorporates both a posteriori (food group intake) and a priori (selection of 
metabolites) information to create dietary patterns.105,123,127,138,139  
However, the RRR procedure cannot account for repeated measures or for 
confounding variables—which could cause the dietary patterns created in Aim 2 to be 
confounded by the structural differences in dietary intake by age. For example, food 
groups eaten at PSV for a child aged 1 year may be very different than for a child aged 5 
years, and this variability may have undue influence in the creation of the dietary 
pattern. The inability to look at dietary pattern structural stability longitudinally is a 
weakness shared by many data-driven dietary pattern methods, including PCA, factor 
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analysis, and RRR. Attempts to examine whether dietary pattern structures (loadings on 
the food groups) are stable with age have been limited to comparing loadings at two 
cross-sectional time points.140–143 
In a pilot study, we applied a new method called three-way PCA which created 
dietary patterns on intake collected at multiple time points in healthy DAISY subjects, 
and described how childhood dietary pattern structures may change over time. Results 
of the analysis indicate that three childhood dietary patterns (indicative of “food pyramid”, “prudent/western”, and “allergy avoidance” diets) are relatively stable from 
ages 1 to 8 years, and a fourth dietary pattern characterized by high intake of fruit, fruit 
juices, and dairy is evident in the first two years of life (unpublished data).  Given that 
cross-sections selected based on the natural history of disease (i.e., pre-seroconversion, 
seroconversion) can include many ages, we might expect dietary pattern structures to 
be confounded by age. Findings from the pilot study motivated our decision to restrict 
at least one cross-section to a single age of subjects (TEDDY, infancy cross-section). 
Availability of and access to both the TEDDY and DAISY studies was a unique 
opportunity for replication. As with the era of large-scale candidate gene studies, 
metabolomics studies are producing many candidate biomarkers that may or may not 
be able to be replicated in independent populations, though replication is universally 
recognized as important.144,145 The decision to organize manuscripts by study 
necessitated the investigation of different disease endpoints to provide novel 
contributions to the literature, precluding the ability to replicate as part of the 
dissertation.  Differences between the studies were also great enough regarding the 
storage and quantification of metabolomics and the assessment tools for dietary intake, 
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that the ability to replicate true associations (if they existed) was questionable. For 
example, assessing dietary intake with food records (TEDDY) over three 24-hour 
periods tends to capture only commonly consumed foods compared to the FFQ (DAISY), 
which may capture rarely consumed foods but tends to overestimate dietary intake. A 
comparison of food groupings available in DAISY and TEDDY highlights differences in 
the food groups available (Appendix A). Additionally, different blood collection 
anticoagulants were used in the two studies that would have contributed to replication 
failure. The TEDDY study used citrate, which has been shown to interfere with primary 
metabolite and lipid quantification,146,147 while DAISY used EDTA anticoagulant. 
Ultimately, replication did not seem feasible for discovering combinations of dietary 
intake associated with IA and T1D. However, a targeted replication could be considered 






METABOLITE-RELATED DIETARY PATTERNS AND THE DEVELOPMENT OF ISLET 
AUTOIMMUNITY 
Abstract 
The role of diet in type 1 diabetes development is poorly understood. Metabolites, 
which reflect dietary response, may help elucidate this role. We explored metabolomics 
and lipidomics differences between 352 cases of islet autoimmunity (IA) and controls in 
the TEDDY (The Environmental Determinants of Diabetes in the Young) study. We 
created dietary patterns reflecting pre-IA metabolite differences between groups and 
examined their association with IA. Secondary outcomes included IAA or GADA as first-
appearing autoantibody, or multiple autoantibodies (mAb+). The association of 853 
plasma metabolites with outcomes was tested at seroconversion to IA, just prior to 
seroconversion, and during infancy. Key compounds in enriched metabolite sets were 
used to create dietary patterns reflecting metabolite composition, which were then 
tested for association with outcomes in the nested case-control subset and the full 
TEDDY cohort. Unsaturated phosphatidylcholines, sphingomyelins, 
phosphatidylethanolamines, glucosylceramides, and phospholipid ethers in infancy 
were inversely associated with mAb+ risk, while dicarboxylic acids were associated 
with an increased risk. An infancy dietary pattern representing higher levels of 
unsaturated phosphatidylcholines and phospholipid ethers, and lower sphingomyelins 
was protective for mAb+ in the nested case-control study only. The risk for mAb+ was 





 Type 1 diabetes affects over 500,000 children globally, making it one of the most 
common metabolic illnesses in children.28 Autoimmune destruction of the insulin-
producing beta-cells in the pancreas results in hyperglycemia and lifelong insulin 
dependency. Genetic risk factors are well described and likely interact with non-genetic 
risk factors to influence disease progression, though exact pathogenesis remains 
unclear.148 The appearance of autoantibodies can be detected as early as 3 months of 
age and defines the beginning of islet autoimmunity (IA), the preclinical stage of the 
disease.10 Efforts to better characterize metabolic dysregulation around the time of 
seroconversion and prior to the detection of autoantibodies may allow earlier 
identification of at-risk children and better understanding of the processes involved. 
 Metabolites reflect the interaction of numerous biological factors, including 
many that may influence the development of autoimmune diabetes, such as genetics, 
microbiome, and dietary intake. Metabolomics differences between IA cases and 
controls mostly have been found at the time of seroconversion, but are inconsistent 
across studies conducted in country-specific populations.95,101,102,104 Previous studies 
indicated that metabolic disturbances exist prior to autoimmunity, and as early as birth, 
in Finnish children who later progressed to type 1 diabetes.96,101,103 The identification of 
generalizable metabolic profiles related to the development of early stages of the 
disease may inform dietary interventions to prevent type 1 diabetes, which have so far 
proven unsuccessful.36 
Traditional investigations of diet in the development of type 1 diabetes has 
examined effects of individual foods or food groups and nutrients such as cow’s 
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milk,36,77,78 fatty acids,79–81,149,150 or vitamin D.151,85,152,86 However, these approaches do 
not account for the complexity of the diet—the effects of single nutrients and foods are 
often too small to identify, or too highly correlated to be separated from each other.100 
Examining combinations of foods and metabolites may better elucidate the role of diet 
in IA, as it can account for synergistic or antagonistic effects of foods or nutrients 
contained in the diet, and differences in how they are processed in the body.  
 We aimed to identify metabolite-related dietary patterns associated with IA in 
the multinational The Environmental Determinants of Diabetes in the Young (TEDDY) 
study (Figure IV-1). We conducted a metabolome- and lipidome-wide association study 
to better characterize plasma metabolites and lipids distinguishing cases and controls 
both at the time of the first autoantibody detection, and prior to its development. We 
created dietary patterns summarizing candidate metabolites identified pre-IA, and 
tested the longitudinal association of those metabolite-related dietary patterns with the 
development of IA.  
 
 
Figure IV-1: Study design for identifying metabolite-related dietary patterns 
associated with the development of IA in TEDDY. 
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Research Design and Methods 
TEDDY Study Design 
TEDDY is an international consortium that enrolled 8,676 newborn infants with 
a high- or moderate-risk class II HLA genotype between 2004 and 2010.110 Participants 
are closely followed for the development of IA or type 1 diabetes, with study visits 
every three months from birth to age 48 months, and every three or six months 
thereafter depending on autoantibody status until age of 15 years. Participating study 
centers include: Georgia/Florida, Colorado, and Washington in the U.S., and Finland, 
Sweden, and Germany in Europe. IA cases are defined by confirmed autoantibody 
positivity  to either insulin (IAA), GAD (GADA), or IA-2 (IA-2A) on two consecutive study samples, the first of which defines the case’s event age. Institutional review board 
approval for the study and written informed consents were obtained for all 
participating children. 
A nested case-control biomarker study was designed using risk set sampling to 
select three controls per IA case (n=418) that had developed in TEDDY as of May 2012. 
Eligible controls were autoantibody-negative at the case’s event age, and further 
matched on clinical center, sex, and family history of type 1 diabetes as previously 
described.116 Secondary outcomes included persistent confirmed positivity to insulin 
only (IAA), GAD only (GADA), or IA2 only (IA-2A) at IA event time. IA-2A was excluded 
as an outcome since very few cases developed IA2 as their first and only persistent 
confirmed autoantibody at IA case-time. Multiple autoantibody positivity (mAb+) was 
defined as any subject positive for more than one autoantibody at IA event time, or who 
developed more than one autoantibody during follow-up.  
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Metabolomics Data Pre-Processing 
Metabolomics abundance measures (metabolites and lipids) were obtained for 
all cases and controls for each available study visit from birth until the case event time. 
Primary metabolites and complex lipids were quantified from citrate plasma using GC-
TOF MS and CSH-QTOF MS data acquisition, respectively, at the NIH West Coast 
Metabolomics Center at the University of California, Davis. GC-TOF MS data were 
acquired as previously described,153 with data processing and compound identification 
using the BinBase algorithm.154 GC-TOF data were sum normalized followed by LOESS 
(locally weighted scatterplot smoothing) normalization. For complex lipids, samples 
were extracted by methyl-tert-butyl ether/methanol/water,155 followed by 
chromatogram peak detection and alignments using Mass Profiler Professional (Agilent, 
Santa Clara, CA). Peaks detected in a minimum of 30% of samples were identified and 
quantification back-filled using the Fiehn laboratory’s LipidBlast spectral library, as 
previously described.120 LOESS followed by batch ratio (QC samples were used to adjust 
sample batch median to global study median) normalization was performed across all 
the samples to estimate and remove analytical variance. 
Prior to transformation, data quality checks included evaluation at the 
metabolite- and sample-level. Metabolites that were not detected in more than 10% of 
samples (6 metabolites), or with a coefficient of variation greater than or equal to 100% 
(286 metabolites) were excluded from further analyses. Samples with missing or zero 
values in greater than 10% of metabolomics features (n=5) or with values more 
extreme than 4 standard deviations above or below the mean in greater than 30% of 
metabolomics features (n=6) were removed from analyses. A total of 853 metabolites 
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and lipids and 11,556 samples passed the quality checks. All metabolites were 
transformed using Box-Cox transformation analysis, and scaled.156  
Dietary Intake and Food Groupings 
Dietary assessment was carried out by 24-hour recall at the first clinic visit at 3-
4.5 months of age, then by 3-day food record every 3 months until 12 months of age, 
and then every 6 months thereafter. TEDDY research staff provided detailed instruction 
and examples to families regarding completion of food records, as previously 
described.84 From quantities of foods and dishes consumed, the amounts of energy and 
single foods contained therein were computed using in-house food record processing 
programs and food composition databases unique to each country.113 The foods and 
dishes (e.g., wheat bread, apple-oat meal) consumed were quantified into main food 
groups (e.g., cereals, fruits and berries, etc.) and subgroups (e.g., wheat, rice, oats, citrus 
fruits, apple, berries, etc.) in grams per day (g/day) of intake. After quantification, the 
three food records were averaged to calculate the mean energy and food intake for each 
study subject on each study visit. Results of detailed harmonization studies of these 
country-specific food composition databases documented that the energy values, 14 
main food groups, and 85 food subgroups used in this study were comparable across 
the TEDDY countries.113  
 For any food record where a subject was indicated as breast fed, we estimated 
the amount of breastmilk consumption using an algorithm developed by the Institute of 
Medicine.157 First, we calculated the estimated energy requirement based on age and 
weight. The difference in the estimated energy requirement and the mean energy 
reported on the food record from food and formula was attributed to breastmilk. We 
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calculated the amount (grams) of breastmilk consumed to achieve that energy intake 
using a conversion factor of energy density per 100g, as follows: 65.3 kcal/100g in 
Finland, 69 kcal/100g in Germany, 68 kcal/100g in Sweden, and 70 kcal/100g in the 
U.S. 
Statistical Analyses 
 Figure IV-2 summarizes the population and data flow for all aims and analyses. 
Metabolites Associated with IA 
 Conditional logistic regression was used to calculate odds ratios (ORs) for the 
association of each transformed metabolite with the development of IA, adjusting for 
high-risk HLA genotype (DR3-DQA1*05:01-DQB1*02:01/DR4-DQA1*03:01-
DQB1*03:02 versus all other), and age at blood draw. Some TEDDY subjects follow a 
long-distance protocol, in which blood is drawn and shipped to clinical centers before 
being processed for biomarker identification. Since plasma primary GC-TOF MS 
metabolic profiles are less stable with centrifugation delay,158 we required an additional 
match for the long distance protocol between case and control samples.  
Metabolomics analyses were run in three cross-sections. First, we examined 
metabolite differences between IA cases and controls at the first detection of 
autoantibody positivity (seroconversion), defined as the first of the two consecutive 
autoantibody positive visits for cases. Then, to identify metabolites and lipids that may 
differentiate IA cases and controls prior to the detection of autoantibodies (pre-
seroconversion) we selected the most recent IA-free visit for cases. Finally, since 
autoimmunity can begin very early in life and both metabolomics and dietary factors 







controls prior to the appearance of autoantibodies in infancy. The “infancy” cross-
section was defined as an IA-free visit at 9 months of age for cases. For controls, the 
visit corresponding to the case visit was selected for all cross-sections. Children positive 
for autoantibodies at 9-months (n=48 IA cases) and their matched controls were 
excluded from the infancy cross-section (Figure IV-2). 
We tested the association of each metabolite with the secondary outcomes 
described above: IAA, GADA, and mAb+. We considered p-value<0.05 significant since 
traditional approaches for multiple comparison correction may be too strict for the 
unusually highly correlated metabolomics data or inappropriate given the exploratory 
nature of our study aims.159 SAS version 9.4 was used for these analyses. 
We also focused on pathway enrichment, given that metabolites may capture 
perturbations in many upstream biological systems thereby complicating interpretation 
of individual associations. Using the ChemRICH metabolomics set enrichment tool,122 
we tested whether groups of structurally similar metabolites were associated with any 
autoantibody outcome. ChemRICH forms non-overlapping groups of metabolites based 
on chemical similarity and ontology mapping.122 It calculated a single p-value for each 
group, and identified the most significant metabolite in each group as the “key 
compound” (http://chemrich.fiehnlab.ucdavis.edu/). Inputs for the ChemRICH analyses 
included the nominal p-value and odds ratio from the individual conditional logistic 
regression models, and chemical structure information from well-characterized 
annotated metabolites and lipids (p=315, Appendix B). Metabolite groups with p-




Metabolite-Related Dietary Patterns Preceding the Appearance of Autoantibodies 
Reduced rank regression (RRR) was used to identify dietary patterns reflecting 
metabolites associated with IA. RRR creates linear combinations of foods (dietary 
patterns) that explain the maximum covariation in a second set of intermediate 
response variables (metabolites),123 thereby capturing disease-related variation in the 
diet rather than general eating behaviors identified from other dietary pattern 
methods.139 We focused dietary pattern analysis on the infancy cross-section, since it is 
prior to the beginning of the autoimmune process and all children were the same age.  
Food groups from the diet record were combined into 43 subgroups based on 
nutrient content and culinary usage.113 Many foods had a large proportion of subjects 
with no reported intake, given that food records only capture dietary intake on three 
days within each study visit window and that many foods may not be introduced yet for 
visits occurring during infancy. Therefore we applied a filtering criteria for inclusion of 
a food subgroup into the dietary pattern analysis, as is common in studies using RRR.133 
Food subgroups that were shown to be comparable across TEDDY countries, and were 
eaten by at least 40% of subjects in infancy were included in the creation of dietary 
patterns, since highly zero-inflated foods might perform sub-optimally. Food subgroups 
were standardized to the age-specific mean and standard deviation of all TEDDY food 
records for dietary pattern analyses. The key compound in each significantly enriched 
metabolite group (identified by ChemRICH) was used as RRR response variables.  
 The number of dietary patterns needed to best explain the variation in 
metabolites was selected using the van der Voet T2 statistic.124 The loadings (or relative 
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weights) of food groups on each dietary pattern and the partial correlation with 
metabolite response variables was used to interpret each dietary pattern.  
Metabolite-Related Dietary Patterns and Risk of IA 
Infancy metabolite-related dietary patterns were first tested in the nested case-
control study using conditional logistic regression as described above. Then we applied 
them to the full TEDDY cohort at 9 months of age, using the food group loadings to 
generate one score per pattern for each subject with complete food records (n=6,845). 
The score indicates how similar the reported dietary intake is to the dietary pattern. 
Multiple dietary patterns were produced as a result of the RRR procedure and could be 
subsequently modeled together because they are statistically independent. 
 Cox proportional-hazards models were used to test the association of 
metabolite-related dietary pattern scores at 9-months on risk of mAb+, adjusting for 
clinical center, high-risk HLA genotype, family history of type 1 diabetes, total energy 
intake, and sex. Time-to-event analyses were performed to evaluate whether 
metabolite-related dietary pattern scores were associated with mAb+ by the age of 6 
years. Cases included those selected for the nested case-control study plus any 
additional cases that developed by January 2018. Given that risk factors for IA may 
differ by age, we restricted follow up to 6 years in the TEDDY cohort to ensure the 
cohort analysis represented a similarly-aged case-population as the nested case-control 
study.  For consistency with the nested case-control study, the time-to-event was 
defined as the time from birth to the appearance of the first persistent confirmed 
autoantibody among IA cases who developed a second persistent confirmed 
autoantibody at any point. Subjects without complete covariate information, those 
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developing mAb+ at 9-months (n=53), or who had no follow-up after 9-months (n=243) 
were excluded from survival analysis (Figure IV-2). 
Results 
Metabolic Dysregulation Apparent at Seroconversion and Infancy 
From the nested case-control study, there were 352 matched sets with 
metabolomics measures for 1 case and at least 1 control at seroconversion (mean (SD) 
case-age=722 (446) days), 366 sets at pre-seroconversion (mean (SD)=625 (412) days), 
and 253 sets at the 9-month infancy visit (mean (SD)=283 (14) days) (Table IV-1). For 
secondary outcomes, 49% of IA cases were positive for IAA, 32% for GADA, and 60% 
for mAb+. The distribution of secondary outcomes was consistent across the 
seroconversion, pre-seroconversion, and 9-month infancy cross-sections. The majority 
of IA cases were from Sweden (32%) and Finland (28%). IA cases were 55% male, 22% 
had a first degree relative, and 12% had their seroconversion blood-draw following TEDDY’s long distance protocol (Table IV-2). The distribution of matched sets by 
matching factors (clinical center, sex, first-degree relative status, and long distance 
protocol) were similar in the secondary outcomes compared to primary IA. 
Approximately 9% of the pre-seroconversion case samples (n=34) occurred during the 







Table IV-1: Description of matched sets (1 case and 1, 2 or 3 controls) for 
metabolomics analyses by outcome and cross-section. 





































































*Secondary outcomes defined as IAA or GADA as first-appearing and only autoantibody at IA case-time (mutually 
exclusive), while mAb+ indicates IA case developed more than 1 persistent confirmed Ab at any point during follow-
up. 
†Age at the time of metabolomics blood draw, in days 
 
 
Table IV-2: Characteristics and outcomes of TEDDY nested case-control 1:3 
matched study at seroconversion. 
 Outcomes 
  IA IAA GADA mAb+ 
Matching Characteristic n (%) n (%) n (%) n (%) 
Clinical Center         
Colorado 51 (14.5) 22 (12.9) 17 (15.0) 30 (14.2) 
Georgia 28 (8.0) 8 (4.7) 12 (10.6) 18 (8.5) 
Washington 32 (9.1) 16 (9.4) 14 (12.4) 15 (7.1) 
Finland 100 (28.4) 59 (34.5) 23 (20.4) 72 (34.1) 
Germany 28 (8.0) 11 (6.4) 9 (8.0) 16 (7.6) 
Sweden 113 (32.1) 55 (32.2) 38 (33.6) 60 (28.4) 
Sex         
Female 158 (44.9) 71 (41.5) 56 (49.6) 91 (43.1) 
Male 194 (55.1) 100 (58.5) 57 (50.4) 120 (56.9) 
FDR/GP Status         
First Degree Relative 79 (22.4) 37 (21.6) 27 (23.9) 53 (25.1) 
General Population 273 (77.6) 134 (78.4) 86 (76.1) 158 (74.9) 
Long Distance Protocol         
Yes 43 (12.2) 17 (9.9) 16 (14.2) 24 (11.4) 





Conditional logistic regression results from the metabolome-wide association 
study indicated metabolic dysregulation in cases compared to matched controls at 
seroconversion and during infancy (Table IV-3, Figure IV-3). Over 6% (p=54) of 
metabolites and lipids were significantly different at p<0.05 among IA cases and 
matched controls at seroconversion, and 7.5% (p=64) in infancy. More metabolites and 
lipids were different by case status when restricting to the mAb+ outcome—10% 
(p=91) were different between mAb+ and controls at seroconversion, and 15% (p=130) 
in infancy. There were few metabolites associated with the secondary outcomes IAA 
first and GADA first in any cross-section (Figure IV-4). 
 
Table IV-3: Summary of individual metabolites significantly associated (p<0.05) 
with diabetes autoimmunity outcomes in three cross-sections*. 
    Outcomes 
    IA mAb+ 
    All OR>1 OR<1 All OR>1 OR<1 
Cross-section p p % p p p % p p 
Seroconversion* 853 54 6.3 21 33 91 10.7 17 74 
Pre-seroconversion 853 27 3.2 8 19 19 2.2 11 8 
Infancy 9-months 853 64 7.5 21 43 130 15.2 20 110 
Conditional logistic regression models adjusted for HLA (DR3/4) and age at blood draw date 
*Visit at which an autoantibody (or autoantibodies) was first detected 
p=number of metabolites 
 
We focused the metabolomics set enrichment analyses on the mAb+ outcome, 
which represented 60% of IA cases and had the largest signal of metabolomics 
differences between cases and controls. ChemRICH identified seven groups of 
chemically similar metabolites that were significantly different among mAb+ cases and 




 Of the metabolite groups identified as different among mAb+ cases, only 
unsaturated phosphatidylcholines (PC) were consistently dysregulated in all three 
analyses (p-value for group in seroconversion=2.1 x 10-5, pre-seroconversion=0.013, 
infancy=2.2 x 10-20), with the majority of the individual metabolites being lower in 
mAb+ cases compared with controls (OR<1) (Figure IV-5). Similarly, 
phosphatidylethanolamines (PE) were lower in mAb+ cases (OR<1) at both 
seroconversion (p-value=0.0047) and in infancy (p-value=2.9 x 10-6).  
Other than PCs and PEs, distinct metabolite groups distinguished mAb+ cases 
from their controls at the time of seroconversion to primary IA compared to during 
infancy prior to the appearance of any autoantibodies (Table IV-4, Figure IV-5). At 
seroconversion, mAb+ cases had lower levels of unsaturated triglycerides (p-value=3.1 
x 10-15), amino acids (p-value=0.0074), diglycerides (p-value=0.014), and aromatic 
amino acids (p-value=0.03), and higher levels of saturated fatty acids (p-value=0.0074). 
In infancy, other phospholipids were significantly protective for mAb+ (majority of 
OR<1), including sphingomyelins (SM, p-value=1.1 x 10-8) and phospholipid ethers 
(EtherPL, p-value=0.0032), along with the glucosylceramides (GlcCer, p-value=4.4 x 10-
5). Three dicarboxylic acids were significantly higher in mAb+ cases compared to 







Figure IV-3: Volcano plot of the association between 853 metabolites and islet 





Figure IV-4: Volcano plot of the association between 853 metabolites and 





Table IV-4: ChemRICH summary of chemically similar metabolite groups 
significantly associated with mAb+ (nominal p-value for group<0.05). 
 
  























76 5 3 0.000021 0.00029 2 1 0.013 0.35 29 28 2.2E-20 6.6E-19
Sphingomyelins 16 10 10 0.000000011 0.00000016
Phosphatidyl-
ethanolamines
10 3 3 0.0047 0.042 3 3 0.0000029 0.000029
Galactosyl-
ceramides
4 2 2 0.000044 0.00033
Dicarboxylic 
Acids
5 3 0 0.0019 0.012
Phospholipid 
Ethers
6 2 2 0.0032 0.016
Unsaturated 
Triglycerides
43 17 15 3.1E-15 8.7E-14
Amino Acids 6 2 2 0.0074 0.042
Saturated FA 7 3 0 0.0074 0.042
Diglycerides 11 3 3 0.014 0.064
Amino Acids, 
Aromatic
4 2 2 0.03 0.12
ChemRICH inputs: p-value and OR from conditional logistic regression models adjusted for HLA (DR34) and age at draw date
InfancyPre-seroconversionSeroconversion




Figure IV-5: Chemically similar metabolite sets identified as significantly 
associated with mAb+ by ChemRICH. Each row is an individual metabolite, grouped 
by ChemRICH set and sorted by log(OR) within each set. Log(OR) > 0 (red) indicates a 
positive association between metabolite and mAb+, whereas log(OR) < 0 (blue) 
indicates an inverse association between metabolite and mAb+. Phosphatidylcholines 
were significantly lower in cases compared to controls in infancy (9-month), just prior 
to seroconversion, and at seroconversion to primary IA. Other phospholipids were 
significantly lower in cases only in infancy, while other metabolite groups, such as 





Infant Metabolite-Related Dietary Patterns and Risk of mAb+ 
 From each of the six groups identified by ChemRICH in infancy, we used the key 
metabolite (most significant one) as a response variable in dietary pattern analyses, 
including: PC (34:3), SM (d41:2) A, PE (34:2), GlcCer (d41:1), adipic acid, and PC (p-
32:0) or PC (o-32:1) (EtherPL).  
 Reduced rank regression identified three dietary patterns that explained 8% of 
the variation in metabolites and 29.3% of the food variation. Food groups factor 
loadings and metabolite variable weights for each dietary pattern are shown in Figure 
IV-6. Infants scoring high on Dietary Pattern 1 ate more non-gluten containing cereals, 
onions, vegetable oils, and fat-free milk, and less breast milk. This diet corresponded to 
higher levels of PE (34:2). Whereas infants scoring high on Dietary Pattern 2 ate diets 
with higher saturated fats, fat-free milk, poultry, and infant formula, and lower in 
potatoes and vegetable oils. This diet corresponded to higher levels of SM (d41:2) A, 
GlcCer (d41:1), and PC (p-32:0) or PC (o-32:1). Finally, 9-month infants scoring high on 
Dietary Pattern 3 ate diets higher in breast milk, red meat, potatoes, and cereals, and 
lower in processed fruits, legumes, and infant formula. High scores on Dietary Pattern 3 
corresponded to higher levels of PC (34:3) and PC (p-32:0) or PC (o-32:1), and lower 




Figure IV-6: Food group loadings and metabolite weights for metabolite-related 
dietary patterns. In total, the three dietary patterns explained 8% of metabolite 
variation and 29.3% of food variation. For food, the radial axis indicates the loading on 
each dietary pattern (Range: -0.6 to 0.4), and is used to interpret which combinations of 
foods are influential in the dietary pattern. Similarly, the metabolite radial axis indicates 
the weight of each metabolite on each dietary pattern (Range: -0.6 to 0.9), indicating 
which combination of metabolites are explained by each dietary pattern. For example, 
subjects scoring high on dietary pattern 1 had diets higher in non-gluten containing 
cereals, onions, vegetable oils, and fat-free milk, and lower in breast milk. This diet 
corresponded to higher levels of PE (34:2). 
 Dietary patterns generated from metabolites and food intake in the nested case-
control study were applied to the full cohort to generate one metabolite-related dietary 
pattern score for each dietary pattern on all 9-month diet records (Table IV-5). 
Subjects developing mAb+ by age 6 years were more likely to have a first-degree 
relative (FDR) with type 1 diabetes and to have high-risk HLA-DR3/4 genotypes. No 
dietary patterns were univariately associated with becoming a case of mAb+. While 
dietary pattern 3 was significantly protectively associated with mAb+ in the nested 
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case-control study (OR=0.67, 95%CI=0.48-0.94, Table IV-6), there was no association 
seen in time-to-event analyses applied to the whole cohort and adjusted for clinical 
center, sex, HLA-DR3/4, and FDR (HR=0.98, 95%CI=0.83-1.16, Table IV-6). No other 9-
month metabolite-related dietary patterns were associated with development of mAb+ 
in the TEDDY cohort. Results did not change in a sensitivity analysis in which we 
adjusted for an additional 17 covariates that TEDDY has identified as associated with 
development of IA (race-ethnicity, maternal education, maternal age, introduction of 
probiotics before 28 days, introduction of probiotics at or after 28 days, weight for age 
z-score at 12 months, and number of minor alleles for rs2476601, rs2816316, 
rs11711054, rs10517086, rs4948088, rs1004446, rs7111341, rs2292239, rs3184504, 
rs3825932, rs12708716) (data not shown). 
Table IV-5: Cohort characteristics of TEDDY children with food records at age 9-
months. 
  mAb+ by age 6 yr mAb- at age 6 yr   
  n % N % p-value 
Total Subjects 300   6237     
Clinical Center         0.196 
Colorado 52 17.33 987 15.82   
Georgia 25 8.33 638 10.23   
Washington 29 9.67 837 13.42   
Finland 77 25.67 1406 22.54   
Germany 23 7.67 365 5.85   
Sweden 94 31.33 2004 32.13   
Female 139 46.33 3075 49.3 0.315 
First degree relative 71 23.67 613 9.83 <0.001 
HLA-DR3/4 169 56.33 2354 37.74 <0.001 
  Mean SD Mean SD p-value 
Age at first Ab (days) 990.1 517.3 --   
Dietary Pattern Scores           
1 -0.055 1.07 0.004 0.98 0.349 
2 -0.076 0.88 0.005 0.93 0.120 








n=147 mAb+ cases 
Cohort† 
n=300 mAb+ cases by 6 years 
Metabolite-related 
dietary patterns 
OR 95%CI HR 95%CI 
1 0.85 0.68 1.05 0.95 0.83 1.08 
2 0.81 0.61 1.08 0.89 0.78 1.02 
3 0.67 0.48 0.96 0.98 0.83 1.16 
*Conditional logistic regression models adjusted for age at metabolomics blood draw and total energy 
†Survival models adjusted for clinical center, sex, FDR, total energy, and HLA DR3/4 
OR=Odds Ratio, CI=confidence interval, HR=Hazard Ratio 
 
Discussion 
 We identified dysregulated metabolism at the onset of and preceding stage 1 
diabetes (mAb+) in a multi-national, prospective type 1 diabetes study. Different groups 
of metabolites distinguished cases and controls depending on whether it was directly 
after or prior to the detection of autoantibodies. Only PC and PE metabolites were 
consistently decreased in mAb+ cases compared to controls. At seroconversion, 
unsaturated triglycerides and amino acid groups were lower among mAb+ cases; 
whereas SM, GlcCer, and EtherPL lipids were lower among mAb+ cases in infancy. 
Infancy dietary patterns explaining choline- and sphingosine- containing lipids were 
not associated with the development of mAb+ in the full TEDDY cohort.  
 Dicarboxylic acids were the only metabolite group we found associated with 
increased risk of mAb+ in infancy. Adipic acid, the key compound of the dicarboxylic 
acids group, is not a substantial component of food other than as a biomarker of jello 
intake,160 and as such was poorly explained by dietary pattern analysis. Other 
dicarboxylic acids associated with increased mAb+ risk included the tricarboxylic acid 
(TCA) cycle intermediaries succinic acid and malic acid. Through their regulation of 
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demethylase activity, succinic acid and other TCA cycle intermediaries may be 
important regulators of DNA and histone methylation,161 which have been implicated in 
pathogenesis of type 1 diabetes.162 While previous metabolomics studies have similarly 
identified early life TCA cycle metabolite levels (glutamic acid, succinic acid) as 
important for future development of type 1 diabetes among Finnish children,96 the 
effects are not always consistent with the present study. Measurement of TCA cycle 
metabolites, particularly citric acid, was limited by the use of citrate tubes for plasma 
collection and storage in TEDDY. Future work should better characterize the role of 
TCA cycle metabolites in type 1 diabetes using plasma stored in a different medium.  
 Sphingolipid metabolism plays a role in diabetic pathologies, including 
regulating beta-cell apoptosis, proinsulin and insulin folding in the endoplasmic 
reticulum, and cytokine secretion.163 The evidence supporting this connection has been 
recently extended from animal models into human islet cells.164 We identified two 
sphingolipid groups as significantly lower in infancy for mAb+ cases versus controls, 
including the SM group, which were previously identified in type 1 diabetes 
metabolomics studies,96,103 and the GlcCer group. As a whole, sphingolipids have been 
characterized as both pro- and anti-inflammatory. Endogenous sphingolipids are 
metabolically involved in T-cell regulation, autoimmunity, and inflammation,165 yet 
consumption of dietary sphingolipids have been linked to anti-inflammatory 
responses.166 The protective effects may operate via changes in gut microbiota or by 
activating other cofactors such as peroxisome proliferator-activated receptor γ 
expression,167 both of which have been implicated in type 1 diabetes,168 While the 
sphingolipid metabolites were explained by Dietary Pattern 2 and trended toward 
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protective, it was only marginally significant in the full cohort analysis. Targeted 
characterization of the relationship between sphingolipid dietary intake and metabolite 
levels might help to disentangle reported contrasting effects, which likely depend on 
other factors such as specific sphingolipid structure and existing metabolic state. 
 We identified choline-containing lipid groups (PC, SM, EtherPL) as protective for 
development of mAb+ at 9 months of age, consistent with previous studies conducted at 
birth and 3 months of age.96,102,103 Choline is important for rapid growth and 
development in infancy, as a constituent of phospholipid cellular membranes. 
Additionally, it may play a role in insulin resistance or energy metabolism, perhaps 
through its role as a methyl donor for epigenetic changes.169 Breastmilk, infant formula, 
and milk are important sources of choline in the infant diet, though the amount and 
type of choline-containing compounds vary widely across dietary sources.170,171 
Correlation of choline-containing compounds with each other, and with breastmilk and 
infant formula were identified in Dietary Pattern 3, which was protective for mAb+ in 
the nested case-control study only.  
 However, no metabolite-related dietary pattern at 9-months was associated with 
the development of mAb+ by the age of six years in the full TEDDY cohort. The percent 
of metabolomics variation explained by the dietary patterns is modest, yet comparable 
to other dietary pattern studies utilizing targeted metabolomics measures.126 The 
remainder of the variability is likely related to other environmental, lifestyle, and 
genomic factors that influence metabolism. 
 There are several factors that could contribute to the lack of dietary pattern 
association found, despite overlap between the mAb+ cases on whom the patterns were 
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created and all mAb+ cases included in cohort analyses. First, untargeted metabolomics 
and 3-day food records may not be measured precisely enough to successfully identify 
disease-related dietary patterns at such a young age where variability in both is large. 
Second, using the most significant metabolite in each group may not be the best choice 
of response variable, which is the variable that determines the ability of reduced rank 
regression to capture disease-related variation in the diet.172 Metabolomics measures 
were further limited because they were quantified from non-fasting samples, which has 
been shown to differentially impact serum metabolic profiles related to dietary 
factors.173  
 Despite the large variation in untargeted metabolomics panels and diet, both of 
which vary by geography in our multi-national setting, we were able to identify 
metabolic dysregulation prior to the detection of autoantibodies that distinguished 
children whose lifetime risk for symptomatic (Stage 3) type 1 diabetes approaches 
100%.174 Our findings confirmed smaller, country-specific studies and expanded the 
knowledge base of metabolite groups in the more heterogeneous TEDDY study 
population. Though results generalize to a broader population than previous studies, 
the very young cases (<= 9-months of age) were excluded from our study. The 
discovery of only one group of metabolites (PCs) that was identified across the pre-
autoimmune period is consistent with other type 1 diabetes studies where the effect of 
non-genetic factors could be age-related or have an effect only during certain 
susceptible windows. While novel application of dietary patterns summarizing 
candidate metabolites did not successfully extend outside of the nested case-control 
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study, the approach may show promise for future work with targeted measurement of 
disease-related metabolites.   
 In summary, we identified metabolomics differences between cases and controls 
both at the time of autoantibody detection, and prior to its development. Metabolomics 
differences were more apparent when comparing the high-risk mAb+ group to controls 
than comparing all cases of IA to controls. Few differences were identified by the type of 
first-appearing autoantibody. Dietary patterns explaining candidate metabolites were 
not significantly associated with development of mAb+ in the full TEDDY cohort. The 
risk for mAb+ was associated with decreased levels of choline- and sphingolipid-related 
metabolomics factors in infancy, possibly due to changes in lipid-related dietary intake.  
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METABOLOMICS-RELATED NUTRIENT PATTERNS AT SEROCONVERSION AND 
RISK OF PROGRESSION TO TYPE 1 DIABETES 
Abstract 
Objective  
 To elucidate the role of diet in type 1 diabetes by examining combinations of 
nutrient intake in the progression from islet autoimmunity (IA) to type 1 diabetes.  
Research Design and Methods  
 We measured 2,457 metabolites and dietary intake at the time of seroconversion 
in 132 IA-positive children in the prospective DAISY study. IA was defined as the first of 
two consecutive visits positive for at least one autoantibody (insulin, GAD, IA-2, or 
ZnT8). By December 2018, 40 children progressed to type 1 diabetes. Intakes of 38 
nutrients were estimated from semi-quantitative food frequency questionnaires. We 
tested the association of each metabolite with progression to type 1 diabetes using 
multivariable Cox regression. Nutrient patterns that best explained variation in these 
significant metabolites were identified using reduced rank regression (RRR), and their 
association with progression to type 1 diabetes was tested using Cox regression 
adjusting for age at seroconversion and high-risk HLA genotype.  
Results  
 In stepwise selection, 22 nutrients significantly predicted at least two of the 13 
most significant metabolites associated with progression to type 1 diabetes, and were 
included in RRR. A nutrient pattern corresponding to intake lower in linoleic acid, 
niacin, and riboflavin, and higher in total sugars, explained 18% of metabolite 
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variability. Children scoring higher on this metabolite-related nutrient pattern at 
seroconversion had increased risk for progressing to type 1 diabetes (HR=3.31, 
95%CI=1.46-7.47).  
Conclusions 
 Combinations of nutrient intake reflecting candidate metabolites are associated 
with increased risk of type 1 diabetes, and may help focus dietary prevention efforts.  
Introduction 
 Type 1 diabetes is characterized by destruction of the insulin-producing beta-
cells in the pancreas, and affects over 100,000 children and adolescents in the U.S.175 
Clinical type 1 diabetes is preceded by a period of detectable and persistent 
autoimmunity to islet antigens, called islet autoimmunity (IA). While the incidence of 
childhood type 1 diabetes has been increasing worldwide for decades,175 the incidence 
of IA appears stable,176 suggesting that an increase in progression from IA to clinical 
diabetes may help explain these incidence trends. Therefore, it is important to identify 
factors influencing progression from IA to type 1 diabetes. 
 Non-genetic factors are involved in the development of type 1 diabetes, which 
also has a well-defined genetic risk component.16 Dietary intake in early life and 
throughout childhood has been implicated in type 1 diabetes risk, though without 
conclusive findings of a single responsible risk factor.177 Higher intake of some foods or 
nutrients at seroconversion has been associated with increased risk of progression to 
type 1 diabetes, including: glycemic load,82 total sugars and sugar-sweetened 
beverages,83 and cow’s milk protein.77 Other dietary factors, including vitamin D intake 
and status,85,178 and omega-3 fatty acid intake and status,79 were not associated with 
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progression. These traditional investigations of individual dietary risk factors may 
oversimplify true dietary exposure since multiple nutrients are contained in foods, and 
nutrients may work synergistically or antagonistically in the body. We sought to 
improve upon previous investigations into diet and progression from islet 
autoimmunity to type 1 diabetes by considering combinations of nutrient intake, or 
nutrient patterns.  
 Our aim was to identify nutrient patterns of intake at seroconversion associated 
with risk of progression to type 1 diabetes in the Diabetes Autoimmunity Study in the 
Young (DAISY), as shown in Figure V-1. To capture disease-related variation in 
nutrient intake, first we conducted a metabolome-wide association study to identify 
metabolites and lipids associated with progression from IA to type 1 diabetes. As 
markers of biological processing and response to nutrition, metabolites have been used 
together with reported dietary intake to elucidate the role of diet in the development or 
prevention of other outcomes, such as cardiovascular disease 179. Next, we used reduced 
rank regression to create nutrient patterns best explaining those candidate metabolites. 





Figure V-1: Study design for identifying metabolite-related nutrient patterns 
associated with progression from islet autoimmunity (IA) to type 1 diabetes. a) 
We conducted a metabolome-wide association study to identify seroconversion 
lipidomics and metabolomics associated with progression to type 1 diabetes by 
December 2018. Significant metabolites and nutrient patterns that best summarized 
them were identified using reduced rank regression. Metabolite-related nutrient 
pattern scores were tested for the risk of type 1 diabetes. b) Of the 213 IA cases 
identified in DAISY by January 2015, 132 had untargeted metabolomics measures and 
dietary intake available at the time of seroconversion. 
 
Research Design and Methods 
Study Design 
 From 1993-2004, DAISY recruited 2,547 children in Colorado who were at high 
risk for developing type 1 diabetes.111 Prospective follow-up for the development of 
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islet autoantibodies and type 1 diabetes is ongoing, and has included clinic visits at 9, 
15, and 24 months, and annually thereafter.180 An IA case is defined by the presence of 
one or more confirmed autoantibody to insulin, GAD65, IA-2, or ZnT8 on two or more 
consecutive clinic visits. Seroconversion is defined as the first visit at which IA was 
detected.  IA cases follow an accelerated protocol with clinic visits every 3-6 months 
until type 1 diabetes is diagnosed by a physician following standardized criteria, 
including typical symptoms of polyuria and/or polydipsia and a random glucose > 11.1 mmol/l or an OGTT with a fasting plasma glucose ≥ 7.0 mmol/l or 2-h glucose > 11.1 
mmol/l.20 
 To identify seroconversion metabolomics and nutrient patterns associated with 
progression from IA to type 1 diabetes, we examined IA cases who seroconverted prior 
to January 2015 and their prospective follow-up for type 1 diabetes through December 
2018.  
Metabolomics Data Acquisition, Normalization, and Pre-Processing 
 Untargeted metabolomics measures were acquired from serum samples using 
GC-TOF MS (primary metabolism), CSH-QTOF MS (complex lipids), and HILIC-QTOF MS 
(biogenic amines), at the NIH West Coast Metabolomics Center at the University of 
California, Davis. Samples were kept at -80°C prior to analysis. Samples were allowed to 
thaw on wet-ice and kept cold during extraction, once thawed samples were inverted 
multiple times to ensure serum homogeneity. Samples were extracted by taking 30 μL 
of serum and performing a liquid-liquid extraction first previously described181 with 
modification, including addition of labeled internal standards for quality control and 
retention time correction.155 The aqueous phase, containing polar metabolites, was split 
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into two equal volumes and dried then re-suspended in 1:1 acetonitrile:water to 
precipitate any remaining lipids. One polar aliquot was then prepared for and analyzed 
by HILIC-QTOF MS/MS.182 The second polar aliquot was analyzed by GC-TOF-MS.183 The 
non-polar phase was analyzed by CSH-QTOF MS/MS for identification and relative 
quantification of complex lipids and free fatty acids.155  
 Peak picking, integration, alignment and annotation of GC-TOF-MS data was 
performed using BinBase.184 Liquid chromatography (LC) data (CSH-QTOF-MS and 
HILIC-QTOF-MS) were processed with MS-Dial,185 and complex lipids were annotated 
with LipidBlast186 and Massbank of North America 
(http://mona.fiehnlab.ucdavis.edu/). MS-FLO was used to remove erroneous peaks and 
reduce the false discovery rate in LC datasets.187  
 After data were collected, annotated and post-processed they were normalized 
to account for any instrument drift, variation, or batch effects which may have occurred. 
Data were normalized by our in-house normalization algorithm; systematic error 
removal using random forest (SERRF).188 SERRF is a QC-based normalization method 
using the random forrest algorithm.189 Briefly, SERRF was designed to be used in place 
of compound independent normalization methods such as locally weighted smoothing 
(LOESS). While LOESS normalizes compounds independently, SERRF takes the 
metabolites’ correlation into consideration and automatically assigns higher weight to 
important compounds. SERRF is nonparametric, nonlinear, less prone to overfitting, 
robust to outliers and noise, and fast to train.   
 After normalization, we performed quality control checks at the sample and 
metabolite level. Samples with a high proportion of features estimated to be zero were 
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considered low abundance (n=2) and excluded from analyses. Each metabolite was 
transformed using box-cox transformation analysis, to improve heteroscedasticity and 
normality.156 Metabolites with a coefficient of variation more than 2 absolute deviations 
from the median were excluded from analyses (p=344), as they may be unreliable or 
produce unstable estimates. Coefficient of variation median and median absolute 
deviations were calculated separately by panel. After quality checks, there were 2,457 
untargeted metabolites for statistical analyses, including 1,905 (77%) unknown 
metabolites.  
Dietary Intake Assessment 
 Dietary intake was measured annually using the Willett semi-quantitative food 
frequency questionnaire (FFQ) starting at age two years. Parents completed an FFQ representing their child’s average intake over the previous year until age 10 years, after 
which study participants self-reported using the Youth Adolescent Questionnaire 
(YAQ). The FFQ has been previously validated,118 and the FFQ and YAQ shown to be 
comparable in the DAISY study population.117 
 The average amounts of daily nutrient intakes were estimated from the FFQ and 
YAQ at the Channing Laboratory, Harvard, MA. Nutrients that were measured 
throughout the DAISY study were considered for inclusion in nutrient pattern analyses 
(p=40). Where available, nutrient variables included the intake from both foods and 
supplements. We used the residual method to calculate the energy-adjusted nutrient 
intakes.100 There were 38 energy-adjusted nutrients available for nutrient pattern 





 IA cases missing metabolomics at seroconversion (n=54), those without a FFQ at 
seroconversion (n=25), those reporting unreasonable total calories (>5,000 kcal, n=1), 
or whose seroconversion visit occurred less than 3 months prior to type 1 diabetes 
diagnosis (n=1) were excluded from all analyses (Figure V-1). All metabolites were 
standardized prior to analyses to allow for direct comparison of the magnitude of 
association with type 1 diabetes. We used Cox regression to identify seroconversion 
metabolomics associated with progression from IA to type 1 diabetes, adjusting for age 
at seroconversion and high-risk HLA (DR3/4) genotype. The time-to-event was defined 
as the time from seroconversion (the first of two consecutive positive visits) to 
diagnosis with type 1 diabetes. We adjusted for multiple comparisons using the 
Benjamini-Hochberg false discovery rate.190  
 Using the most significant metabolites identified in discovery (minimum FDR q-
value), we used reduced rank regression (RRR) to identify nutrient patterns that best 
explained metabolite variation. RRR helps summarize high-dimensional data by 
creating linear combinations of nutrients (nutrient patterns) that maximize the 
variance explained in a set of response variables (metabolites).123 We reduced the 
number of nutrients included in RRR by first applying a stepwise regression selection 
procedure for each metabolite.133 Nutrients that significantly predicted at least 2 
metabolites (p-value<0.1, Appendix C) were included in nutrient pattern analysis. 
Energy-adjusted nutrient intakes were standardized prior to the RRR. Results of RRR 
included metabolite weights, nutrient loadings, and a nutrient pattern score for each 
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participant, indicating how similar their intake was to the nutrient pattern. Weights and 
loadings more extreme than ±0.2 were used to interpret the nutrient pattern.  
 We tested the association of metabolite-related nutrient pattern scores with 
progression from IA to type 1 diabetes using Cox regression. For comparison with the 
nutrient pattern, we included an additional analysis testing individual nutrient 
associations with progression from IA to type 1 diabetes for nutrients that loaded 
strongly (more extreme than ±0.2) on the nutrient pattern. All multivariable Cox 
regression models were adjusted for age at seroconversion and high-risk HLA (DR3/4) 
genotype. SAS 9.4 (SAS Institute Inc., Cary, NC, USA) was used for all statistical analyses.  
Results 
 Of 132 IA cases with metabolomics and dietary intake measured at the time of 
seroconversion, 40 progressed to type 1 diabetes by December 2018. Characteristics of 
the study population are shown in Table V-1. Type 1 diabetes progressors were 48% 
male, mostly non-hispanic white, and 63% had a first-degree relative with type 1 
diabetes. These characteristics were similar in the non-progressor group. However, 
compared to non-progressors, those who progressed to type 1 diabetes had higher-risk 
HLA genotypes (43% versus 28%) and seroconverted to IA positivity at younger ages 
(5 years versus 7.8 years).  
From individual multivariable Cox regression models, 201 metabolites (8%) had 
nominal associations (p-value<0.05) with risk of progression to type 1 diabetes (Figure 
V-2). None of these associations reached significance after adjustment for multiple 
comparisons (q-value<0.05). The 13 metabolites that were tied at the minimum q-value 
of 0.3451, including threonine, histidine, choline, and 10 unknown compounds from the 
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biogenic amines and complex lipids panels, were used in the nutrient pattern analysis. 
Mass spectra for the compounds are included in Figure V-3. The majority of nominally 
significant metabolites were associated with increased risk of progression to T1D 
(Figure V-2). 
 
Table V-1: Characteristics of 132 IA cases at seroconversion 
  
Progressed to type 1 
diabetes (n=40) 
Non-progressors 
(n=92)   
  n % n % p-value* 
Male 19 47.50 45 48.91 0.883 
Non-Hispanic white 36 90.00 68 73.91 0.079 
High-risk HLA (DR3/4) 17 42.50 26 28.26 0.046 
First degree relative with 
type 1 diabetes 25 62.50 52 56.52 0.595 
  Mean SD Mean SD   
Age (years) 5.00 3.82 7.83 4.28 0.025 
Total calories 2146.04 492.47 2077.66 738.63 0.811 
*From Cox regression      
 
To identify nutrient patterns using RRR, we first selected nutrients that were 
significant predictors of the 13 metabolites identified in discovery. Stepwise selection 
results indicated that 22 of 39 nutrients predicted at least 2 metabolites (Appendix C). 
From RRR, one nutrient pattern was identified that explained 18% of metabolite 
variation and 5% of nutrient variation. The metabolite weights and nutrient loadings 
that define the nutrient pattern are shown in Figure V-4. A higher score on the nutrient 
pattern corresponded to a diet with higher intake of total sugars, vitamin C, and 
monounsaturated fat, and lower in linoleic acid, niacin, riboflavin, vitamin K, vitamin 
B12, and caffeine (Figure V-4a). Higher scores on the nutrient pattern also 
corresponded to higher amounts of unknown metabolites hilic_291, hilic_294, hilic_179, 
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hilic_353, hilic_1015, hilic_383, and lower amounts of hilic_243 (Figure V-4b). 
Annotated metabolites threonine, histidine, and choline were poorly explained by the 
nutrient pattern, as indicated by weights closer to 0.  
In multivariable Cox regression, nutrient pattern scores at seroconversion were 
associated with increased risk of progression from IA to type 1 diabetes (Figure V-4c, 
HR=3.31, 95%CI=1.46-7.47). In analyses of the nine nutrients that loaded high on the 
nutrient pattern, only vitamin B12, riboflavin, niacin, and total sugars had significant 
individual associations with progression from IA to type 1 diabetes. 
  
 
Figure V-2: Cox regression results showing the association of 2,457 metabolites 
with progression from IA to type 1 diabetes. 201 metabolites (8%) had nominal p-
value<0.05 (above the guideline), and none were significant at q-value<0.05. The 13 
labeled metabolites had the minimum q-value of 0.3451 and were selected for nutrient 
pattern analyses.  These included threonine, histidine, choline, and 10 unknown 
compounds. Unknown compounds were labeled by the untargeted platform on which 








Figure V-4: A seroconversion metabolite-related dietary pattern and its 
association with progression from IA to type 1 diabetes. One dietary pattern 
explained 5% of nutrient variation and 18% of metabolite variation. a) The loadings 
indicate which combinations of nutrients defined the nutrient pattern scores. b) The 
weights indicate which metabolites were best explained by the nutrient pattern. c) 
Multivariable Cox regression results showing the associations of the nutrient pattern 
score and individual nutrients in progression from IA to type 1 diabetes. 
  
Conclusions 
 We identified a nutrient pattern of intake at seroconversion that was 
significantly associated with increased risk of progression to type 1 diabetes. Higher 
nutrient pattern scores (and increased risk of progression) corresponded to higher 
intake of total sugars, vitamin C, and monounsaturated fat, and lower in linoleic acid, 
niacin, riboflavin, vitamin K, vitamin B12, and caffeine.  Accounting for combinations of 
nutrient intake in the diet using a nutrient pattern score resulted in a stronger 
association with progression to type 1 diabetes (HR=3.31) than the individual nutrients 
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highly contributing to the pattern (HR range=0.56-1.45), and the metabolites used to 
inform the pattern (HR range=0.52-1.9). 
 Several of the nutrients that highly contributed to the nutrient pattern have been 
investigated in the development of IA or type 1 diabetes for years, often resulting in 
small or inconsistent associations with disease endpoints. For example, higher intake of 
total sugars was previously associated with increased risk of progression in DAISY 83. 
Dietary intake of the omega-6 fatty acid, linoleic acid, was not associated with 
progression from IA to type 1 diabetes.79 However, linoleic acid status has been 
inconsistently identified as protective for development of IA.150 Similarly, the niacin 
derivative nicotinamide was protective for type 1 diabetes in mice, but shown to be 
ineffective in a prevention trial.38 The failure to account for the inter-relationship 
between nutrients may explain the inconsistencies surrounding the role of dietary 
intake in type 1 diabetes development.  
 Other nutrients contributing to the pattern have not been directly studied, but 
have plausible connection to type 1 diabetes. For example, riboflavin191 and vitamin K 
(K1, phylloquinone)192 have antioxidant properties that may protect islet cells from 
destruction by free radicals and oxidative stress. Through its role as a cofactor in one-
carbon metabolism, vitamin B12 affects DNA methylation, which is also implicated in 
the disease process (cite methylation). Notably, vitamin C contributes in an unexpected 
direction to the nutrient pattern. Due to its antioxidant and anti-inflammatory 
properties, vitamin C would be expected to have an inverse relationship with risk of 
progression to type 1 diabetes. We speculate that the correlation between vitamin C 
and sugars intake in foods may explain this finding. 
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 The metabolite discovery was primarily used as a means to capture meaningful, 
disease related variation in nutrient pattern intake. However, a broad conclusion of our 
metabolomics findings indicate that metabolic differences at seroconversion distinguish 
which IA cases will go on to type 1 diabetes, similar to previous studies comparing IA 
cases and type 1 diabetes cases to autoantibody negative controls.95,96 Though 
conducted in different disease stages, each study has identified various amino acids as 
dysregulated prior to the development of different disease endpoints. In our study, 
however, threonine and histidine were poorly correlated with diet and therefore less 
influential in the nutrient pattern. The other study comparing IA cases to type 1 
diabetes cases investigated the lipidome in cord blood.193 The majority of our candidate 
metabolites were unknown compounds measured on the HILIC panel, making 
comparison infeasible. 
 The thirteen candidate metabolites were mostly associated with increased risk 
of progression to type 1 diabetes. While these associations were only nominal, our 
nutrient pattern explained over 18% of metabolite variability—over three times the 
amount of variability explained in previous dietary pattern studies,128 and studies of 
individual dietary factors and targeted metabolites.126 This suggests that the 
metabolites used as response variables for identifying the nutrient pattern are related 
to nutrition. Future work should identify and annotate these unknown compounds, and 
consider the strong correlation between metabolites which makes the use of typical 
multiple comparison procedures too strict. The novel use of nutrients rather than food 
groups in pattern analysis likely contributes to the increased variability explained by 
the nutrient pattern—nutrient intakes have more continuous distributions and may 
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perform better in correlation-based analyses such as RRR. While nutrient patterns may 
be harder to interpret than dietary patterns of food, nutrients are more comparable 
across different populations and therefore may be more amenable to the development 
and cross-cultural implementation of dietary interventions to prevent type 1 diabetes.  
 As hypothesized, examining nutrient intakes in combinations, to account for 
their correlation in intake and in biological processing, resulted in a stronger magnitude 
of association than any of the individual constituent nutrients. The relationship of 
highly contributing nutrients to the nutrient pattern is consistent with existing 
literature and hypotheses, suggesting that the contents of the diet may work in 
combination to affect the development of type 1 diabetes, and should be considered 
jointly in future work.  
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 Using newer nutritional epidemiologic methods, this dissertation explored the 
role of metabolomics and dietary patterns in the nutrition etiology of type 1 diabetes. 
First, we identified individual metabolites and chemically similar metabolite groups 
associated with the development of mAb+ and T1D in metabolome-wide association 
studies of two prospective cohorts (TEDDY and DAISY). Candidate metabolites were 
used to capture disease-related dietary and nutrient patterns, which were subsequently 
tested for association with disease endpoints. In TEDDY, a dietary pattern explaining 
metabolites in infancy was associated with decreased risk of mAb+ but was not 
generalizable when applied to similarly at-risk infants. In DAISY, a nutrient pattern 
explaining unknown metabolites at seroconversion was associated with increased risk 
of progression to T1D. 
 We made significant and novel contributions to the understanding of 
metabolomics in the natural history of T1D, though the metabolomics discovery was 
primarily used as a means for identifying disease-related variation in dietary intake. 
Our DAISY study was the first investigation of metabolomics in T1D development in a 
U.S. population, and by far had the best coverage of the metabolome—we measured 
almost 2,500 metabolites, in contrast to previous studies which detected anywhere 
from 106102 to 54095 metabolites. With participants from the U.S., Finland, Germany, 
and Sweden, the TEDDY study had a larger sample size representing more geographic 
areas than the smaller, country-specific studies of metabolomics in T1D risk previously 
conducted in Germany,95 Sweden,102 Norway,104 and Finland.96,101,103,193   
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Increased sample size, a more generalizable population (multi-national), and 
greatly expanded coverage of the metabolome allowed us to comprehensively 
characterize sphingomyelin, choline, and TCA cycle dysregulation in infancy that may 
lead to the development of mAb+ later in life. Previous studies have identified a few 
compounds in each of these classes; however, direct comparisons with them are 
complicated by the varying number of metabolites tested, the stage of disease studied, 
and the time at which metabolites were measured. For example, only two101,104 of the 
seven previous metabolomics studies conducted in prospective T1D cohorts also 
examined cases positive for multiple autoantibodies compared to controls. Of those, one 
measured only lipidomics (p=159) in cord blood, and the other measured only 
metabolomics (p=279) repeatedly over time beginning at 3 months.  
Comparison of our key metabolomics findings from the DAISY study with 
previous literature is similarly complicated. Only three of the 13 metabolites important 
for progression from IA to T1D were annotated—many metabolomics studies either 
exclude unknown compounds from analyses, or fail to provide distinguishing 
characteristics (e.g., mass spectra) for them. Of the seven previous prospective 
metabolomics T1D studies, only the most recent investigations in Finland compared 
T1D cases to IA cases who did not progress to T1D; however, this study only included 
annotated compounds in analyses.103,193 These difficulties highlight current challenges 
for the use of high-throughput metabolomics in epidemiologic research.  
 Metabolomics is one of the newer “—omics” fields to gain popularity in human 
research. The increasing technological capability and decreasing cost of 
comprehensively interrogating small molecules in a biospecimen contributes to its 
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growing use, which in turn is driving a period of rapid growth and progression in the 
field. For example, in only five years between the acquisition of TEDDY and DAISY 
metabolomics data, significant improvements were made to compound deconvolution, 
identification and normalization methods. These, and other, changes resulted in a 
different number of metabolites and proportion of annotated metabolites available for 
statistical analyses in our studies, despite using the same two metabolomics platforms.  
Differently shaped volcano plots from the MWAS discoveries in the two studies 
highlight the potential impacts of changes to platforms or analytical pipelines over time. 
In the TEDDY study, the lipids were mostly protective for the development of outcomes 
and represented the highest proportion of metabolites tested, giving the volcano plots a 
heavier left cloud (OR<1). The DAISY volcano plot has the opposite skew, with the 
majority of candidate probes in the right cloud (HR>1). Interrogation of different 
disease endpoints may explain this difference—perhaps early life metabolomics 
signatures are protective for mAb+, while seroconversion metabolomics differences 
reflect only the increased risk for progression to T1D. Similarly likely, however, the 
right-skewed volcano plot in DAISY reflects the addition of the HILIC panel, which 
doubled the total number of metabolites tested, many of which were associated with 
increased risk of outcome. Similarly, the TEDDY volcano plots showed a pattern of 
metabolites with extreme magnitudes of association that do not achieve significance, 
near the 0 limit of the OR. Further investigation revealed that those metabolites had 
little variability, which led to unstable estimates of association. Changes to the pre-
processing pipeline to filter metabolites with both extremely high and extremely low 
coefficient of variation removed that artefact, giving the DAISY volcano plot a different 
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shape. Finally, standardization (mean, standard deviation) of metabolites in the DAISY 
study also changed the shape of the volcano plot—giving it a butterfly, rather than 
cloud, shape. Changes to pre-processing and analytical pipelines complicates 
comparisons between metabolomics studies, both internal to our own two studies, and 
externally to other metabolomics studies of type 1 diabetes. 
Limitations of available statistical methods may also influence the ability to 
discover metabolites strongly, significantly, and specifically associated with disease 
endpoints using high-throughput metabolomics. The need to account for an unknown 
background of metabolites that should be detectable in biospecimens and for the 
unusually highly correlated features (compared to other –omics) are two specific 
challenges that should be addressed. Both of these attributes may have influenced our 
finding of less extreme p-values and adjusted p-values in the much larger and better-
powered TEDDY study than in the smaller DAISY study. Unlike genomics, which has 
matured over decades of research in humans, metabolomics lacks normative 
procedures for almost all parts of the pipeline from bench to publication. 
Standardizing protocols, analytical pipelines, and developing appropriate 
statistical methods will greatly improve the utility, interpretation, and reproducibility 
of metabolomics findings in epidemiologic research. Specific to our findings of 
metabolomics in T1D, immediate next steps include: 1) better characterization of the 
relationship between annotated and unknown metabolites to appropriately be able to 
adjust for multiple comparisons, 2) examination of longitudinal changes in 
metabolomics prior to disease development utilizing the rich TEDDY resource with 
measurements every 3 months since birth, and 3) identification of unknown 
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metabolites highly explained by the T1D-related nutrient pattern identified in DAISY. 
Despite the challenges of conducting research in a new and rapidly changing field, our 
metabolomics discovery was useful for capturing dietary and nutrient pattern intake 
related to T1D risk.  
With our investigation of dietary patterns, we made significant and novel 
contributions to both nutrition epidemiology and to the nutrition etiology of T1D.  Ours 
were the first two studies in the nutrition literature of T1D risk to consider dietary 
patterns—previous investigations focused solely on evaluating nutrient or food group 
risk factors individually.76,78,83  In the DAISY study, the combination of nutrient intake 
best explaining unknown metabolites was more strongly associated with T1D risk than 
any of the constituent nutrients or metabolites that defined the pattern. Higher nutrient 
pattern scores (and increased risk of progression) corresponded to higher intake of 
total sugars, vitamin C, and monounsaturated fat, and lower intake of linoleic acid, 
niacin, riboflavin, vitamin K, vitamin B12, and caffeine. Many of the constituent 
nutrients to the pattern have been inconsistently associated with T1D for decades 
(Table VI-1),87,177 providing some confidence in the validity of the pattern identified. 
Other nutrients, such as vitamin C, riboflavin, and vitamin K were novel to this 
dissertation, and provided evidence that consideration of the whole diet is important in 





Table VI-1: Summary of previous individual findings for constituent nutrients of 
the nutrient pattern associated with increased risk of progression from IA to T1D. 
 
The infancy dietary patterns identified in TEDDY were less successful—they 
explained less metabolite variation than the nutrient patterns (8% versus 18%) and 
were less strongly associated with disease (OR=0.67 versus HR=3.31). The investigation 
of two different stages in the natural history of T1D is perhaps the largest distinction 
between our two studies, and may explain why patterns explaining mAb+ were less 
successful than patterns explaining progression to T1D. Risk factors affecting 
development of IA are often different than those affecting progression to T1D.11 
Therefore, it is possible that diet is more influential after the appearance of 




Direction of Pattern 
Intake Associated with 
Increased T1D Risk   
Previous Individual Findings Hypothesis 
Total Sugars   Total sugars at IA =  T1D  
Linoleic Acid 
(LA)  
LA at IA ≠ T1D 
 LA =  IA and ≠  IA  
Niacin   Nicotinamide =   T1D (MICE) Nicotinamide ≠  T1D (HUMANS)  




Vitamin K   
Vitamin C   
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The dietary pattern associated with the development of mAb+ in the nested 
case-control study association did not reproduce when applied to the full TEDDY 
cohort. However, this may not indicate less success than the nutrient patterns in DAISY, 
as there were insufficient additional IA cases in DAISY to investigate replication of the 
nutrient pattern. Since replication of RRR dietary patterns in independent population is 
generally recommended,172 future investigation of both nutrient and dietary patterns in 
an independent population will lend more confidence to the generalizability of our 
findings. 
 Other reasons for the differences in our findings between studies may stem from 
differences between TEDDY and DAISY. In TEDDY, dietary intake is collected by food 
records covering three 24-hour periods, whereas DAISY collects FFQs covering average 
diet in the previous year. While both methods have limitations (the food record may not 
capture infrequently eaten foods, the FFQ overestimates intake), dietary patterns 
identified using RRR have been shown to be comparable for both assessments among 
adolescents.130 TEDDY dietary intake is also complicated by the need to harmonize 
national food composition databases between four countries.112 Dietary pattern 
procedures founded on the correlation structure between food intake may suffer from 
residual heterogeneity across countries, despite extensive harmonization efforts. The 
slightly different distribution of mAb+ cases by country in the nested case-control 
(Table IV-2) versus cohort (Table IV-5) analyses may partially explain why the 
protective association of the TEDDY dietary pattern with mAb+ did not reproduce.  
 Alternately, less successful identification of disease-related dietary patterns in 
TEDDY compared to DAISY may relate to differences in our patterns approach between 
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the studies. While RRR was used for both studies, the selection of response variables 
(and their correlation structure) heavily influences the resulting pattern.172 Indeed the 
pattern cannot be interpreted independently of the response variables. Our selection of 
response variables differed by study, as they were determined by the metabolomics 
discovery Aim conducted independently in TEDDY and DAISY. While we only 
considered annotated metabolite groups as identified by ChemRICH enrichment 
analysis in TEDDY, we allowed for the inclusion of unknown metabolites in DAISY 
where selection was based solely on significance. The difference in metabolite 
variability explained by the patterns may indicate that the unknown metabolites were 
more strongly related to diet, or it may reflect that the more continuously distributed 
nutrients perform better in pattern analysis than food groups.  The identification of 
patterns using nutrients rather than food groups was a major difference between the 
approaches, and a novel contribution of this dissertation to dietary patterns literature.  
 Much like metabolomics, the data-driven dietary patterns literature has few 
normative procedures, leaving much room for improvement in the search for 
combinations of dietary factors that may affect T1D risk. For example, by adding a 
filtering step to include only the nutrients that correlated well with metabolite response 
variables, we likely improved our ability to detect patterns associated with T1D. Similar 
filtering of the metabolites (or other response variables) to include only diet-related 
variables in RRR would likely improve the derivation of patterns associated with 
disease endpoints, if they truly exist. Prior to RRR, we adjusted our nutrient variables 
for total energy using the residual method.100 Extending this method to additional 
potential confounders of dietary intake and response variables would allow for a less 
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biased interpretation of how dietary risk factors explain response variables. Studies 
with long-term longitudinal follow-up throughout childhood and adolescence (such as 
TEDDY and DAISY), would benefit from statistical methodological improvements to 
allow for repeated measures in the creation of patterns. To enhance the ability to 
compare patterns across populations, nutrient patterns should be further explored as 
they may be easier to harmonize across dietary assessment methods and cross-
nationally.  
 While many general improvements could be made in the search for 
combinations of dietary risk factors that may influence T1D development, specific next 
steps generated from this dissertation include: 1) refinement and simplification of the 
nutrient pattern to enhance the ability to reproduce in other populations,194 2) 
replication of T1D-related nutrient patterns in the TEDDY study, and 3) investigation of 
additional systems-level biological changes (transcriptome, proteome, etc.) that might 
mediate the effects of the nutrient pattern on progression to T1D.  
Dietary patterns, foods, and nutrients are inextricably linked,195 yet their 
interconnection is insufficiently studied in etiologic research of T1D. As with many 
other nutrition-related complex diseases, multiple nutrients and foods have been 
weakly or inconsistently implicated in the disease process. Feasibility of a dietary 
intervention in young children has been established,35,36 and at-risk populations for 
intervention are being collected via population-based screening studies.41,42 
Identification of an effective intervention is the crucial next step for nutrition research 
in T1D, which could grow from the foundation built in this dissertation project.  
87 
 
We established that investigating complex dietary intake and related molecular-
level changes is an important part of the ongoing search for risk factors amenable to 
intervention in children. In addition to the future work specifically outlined above, 
advancement of the field studying the nutrition etiology of T1D might benefit from a 
framework shift from a one-at-a-time approach, to the “top down approach” that has 
successfully been used to develop dietary guidelines to prevent CVD.196 After 
establishing evidence of dietary patterns associated with disease (the Mediterranean 
Diet), the role of foods (nuts, olive oil) and action of nutrients  within those foods (fatty 
acids, polyphenols) were examined to provide context, explanation, and possible 
mechanisms.195  This project provided evidence of system-level dysregulation of lipids 
in infancy that occur prior to the appearance of autoimmunity, and that may relate to 
dietary intake. As breastmilk was the most highly contributing food to the protective 
dietary pattern (Figure IV-6), understanding its nutrient content and potential 
mechanisms in T1D development might be a logical next step. We also identified 
patterns of nutrient intake including known and novel individual factors that influence 
progression from seroconversion to T1D. Characterization of the foods providing those 
nutrients, and investigation of the novel nutrients contributing to the pattern are 
important extensions from the pattern to the food and nutrient level. Replication and 
fine-tuning of the patterns identified here is a necessary next step in this process. 
Complex, chronic diseases such as T1D are increasing worldwide. Despite  
general consensus that diet may act as an environmental (non-genetic) risk factor 
responsible for these increases and decades of investigation into putative “triggers” of 
disease processes, identification of a single causative dietary factor remains elusive in 
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T1D research. As demonstrated by this dissertation, expanding our methodological 
repertoire beyond individual risk factor epidemiology will improve our understanding 
of the disease process, and ultimately lead to more effective interventions to prevent, 
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TEDDY AND DAISY FOOD GROUPINGS 
TEDDY Food Groups and 
Subgroups 
DAISY Food Groups and Serving Size 
CEREALS   
Rice 
White rice (1 cup) 
Brown rice (1 cup) 
Wheat 
Dark bread (1 slice) 
White bread (1 slice)   
Wheat germ (1 tbs) 
Rye   
Oats Cooked breakfast cereal e.g. oatmeal (1 cup) 
Barley   
Corn   
Other gluten free flours and starches   
FRUIT AND BERRIES   
Citrus fruit 
Grapefruit (1/2)  
Oranges (1) 
Apple Fresh apples or pears (1) 
Berries 
Blueberries, fresh, frozen or canned (1/2 cup) 
Strawberries, fresh, frozen or canned (1/2 cup) 
Other fruits 
Bananas (1) 
Cantaloupe (1/4 melon) 
Watermelon (1 slice) 
Peaches, Apricots or Plums (1 fresh, or 1/2 cup 
canned) 
Canned fruits   
Dried fruits and berries 
Prunes (1/2 cup) 
Raisins (1 oz. or small pack) or grapes  
Citrus juice 
Grapefruit juice (small glass) 
Orange juice (small glass)  
Apple juice Apple juice or cider (small glass) 
Berry juices   
Other fruit juices Other fruit juices (small glass) 
Mixed Juices   
Juices, mixture of vegetable and fruit   
VEGETABLES   
Potatoes 
French fried potatoes (4 oz.) 
Potato chips (small bag or 1 oz.) 
Potatoes, baked, boiled (1) or mashed (1 cup) 
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Roots, sweet potatoes 
Carrots (1 whole or 1/2 cup cooked) 
Yams or sweet potatoes (1/2 cup) 
Leafy vegetables 
Iceberg or head lettuce (1 serving) 
Kale, mustard or chard greens (1/2 cup) 
Romaine or leaf lettuce (1 serving) 
Spinach, cooked (1/2 cup) 
Spinach, raw as in salad  
Cabbages 
Broccoli (1/2 cup) 
Brussels sprouts (1/2 cup) 
Cabbage or coleslaw (1/2 cup) 
Cauliflower (1/2 cup) 
Fruit vegetables 
Corn (1 ear or 1/2 cup frozen or canned) 
Tomatoes (1) 
Yellow (winter) squash (1/2 cup) 
Eggplant, Zucchini, or other summer squash 
(1/2 cup) 
Onions   
Mushrooms   
Legumes, beans, peas 
Beans or lentils, baked or dried (1/2 cup) 
Peas or lima beans (1/2 cup fresh, frozen, 
canned) 
String beans (1/2 cup) 
Vegetables, dried   
Vegetables, canned   
Vegetable juices Tomato juice (small glass) 
SOY   
Soy beans   
Soy products Tofu or soybeans (3-4 oz.) 
Soy milk   
Soy dessert   
Soy sausage   
Soy sauce   
NUTS, SEEDS   
Nuts, seeds 
Nuts (small packet or 1 oz.) 
Peanut butter (1 Tbs) 
FATS AND OILS   
Vegetable oils   
Solid vegetable fat   
Fish oil   
Animal fats   




Margarines Margarine (pat) added to food or bread, exclude 
use in cooking 
Butter-margarine mixtures   
MILK AND MILK PRODUCTS   
Breast milk   
Fat-free milk   
Low-fat milk Skim or low fat milk (8oz. Glass) 
High-fat milk Whole milk (8 oz. glass) 
Other animal milk    
Creams Cream e.g. coffee, whipped (TBS) 
Ice cream 
Milk shake or frappe (1) 
Ice cream (1/2 cup) 
Ice cream sundae 
Sour milk and sour milk products Yogurt (1cup) 
Cheese 
Other cheese, e.g., American, etc., plain or as 
part of a dish (1 slice or 1oz. Serving) 
Cream cheese (1 oz) 
Cottage or Ricotta chz (1/2 cup) 
Whey   
NON-DAIRY PRODUCTS   
Non-dairy products 
Sherbet or ice milk (1/2 cup 
Non-Dairy Coffee Whitener (tsp) 
MEAT AND MEAT PRODUCTS   
Pork   
Beef 
Hamburger (1 patty)  
Beef, pork, or lamb as a main dish (4-6oz.) 
Poultry 
Chicken or turkey, with skin (4-6 oz.) 
Chicken or turkey, without skin (4-6 oz.) 
Lamb, goat, horse   
Game   
Processed meats and sausages 
Processed meats, e.g., sausage, Salami, bologna, 
etc. (piece or slice) 
Bacon (2 slices) 
Organ meats/offals Liver (3-4 oz.) 
FISH AND FISH PRODUCTS   
Fresh and frozen fish 
Other fish (3-5 oz.) 
Dark meat fish (3-5 oz.) salmon, sardines 
Processed fish   
Canned fish Canned tuna fish (3-4 oz.) 
Shellfish, other seafood Shrimp, lobster, scallops as a main dish 
EGGS   
Eggs Eggs (1)  
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BEVERAGES   
Coffee   
Tea   
Light Beverages including cola 
Other low calorie carbonated beverage, e.g. 
Fresca, Diet 7-up, Diet Ginger Ale 
Low-calorie caffeine-free cola, e.g. pepsi free  
Low-calorie cola e.g. tab with caffeine 
Sugar sweetened beverages 
including cola 
Hawaiian punch, lemonade, or other non-
carbonated fruit drinks (1 glass, bottle, can) 
Other carbonated beverage with sugar e.g. 7-up, 
ginger-ale 
Coke, pepsi, or other cola with sugar 
Caffeine free coke, pepsi, or other cola with 
sugar 
Alcohol   
CONFECTIONARY   
Sweets Candy without chocolate (1 oz.) 
Chocolate chocolate pieces e.g. Hershey's, M&M's 
TEDDY ONLY: INFANT FORMULAS   
Regular cow’s milk based infant 
formulas   Partially hydrolyzed cow’s milk 
based infant formulas   Fully hydrolyzed cow’s milk based 
infant formulas and amino acid 
(elemental) formulas   
Soy base infant formulas   
Other non-dairy infant formulas   
Other animal (dairy) infant formulas   
TEDDY ONLY: MISC.   
Ketchup    
  DAISY ONLY: COMPLEX FOODS 
  Brownies (1) 
  Cake ready made (slice) 
  Cake homebaked (slice)  
  other Candy bars, e.g. snickers, Milky Way, mars 
  Cookies ready made (1)  
  Chowder or cream soup (1 cup) 
  Cold breakfast cereal (1 cup) 
  Cookies home baked (1)  
  




  Crackers, triskets, wheat thins,etc. (1) 
  Doughnuts (1) 
  English muffins, Bagels, or rolls (1) 
  Hot dogs (1) 
  Jams, Jellies, preserves, syrup, or honey (1 Tbs) 
  Mayo or other creamy salad dressing (1 TBS) 
  Mixed vegetables (1/2 cup) 
  Muffins or biscuits (1) 
  Oil and vinegar dressing, e.g. italian (1 TBS) 
  Onion rings, french fried 
  Pancakes or waffles (serving) 
  Pasta, e.g. spaghetti, noodles, etc. (1 cup) 
  Pie, ready made (slice) 
  Pie, homemade (slice) 
  Pizza (2 slices) 
  Popcorn (1 cups)  
  Red chili sauce (1 TBS) 
  
Beef, pork, or lamb as a sandwich or mixed dish, 
stew casserole, lasagna 
  
Sweet roll, coffee cake or other pastry ready 
made (serving)  
  
Sweet roll, coffee cake or other pastry 
homebaked (serving)  







CHEMICALLY ANNOTATED METABOLITES USED IN CHEMRICH METABOLOMICS 
SET ENRICHMENT ANALYSIS (TEDDY) 





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































DAISY NUTRIENTS EVALUATED FOR SIGNIFICANTLY PREDICTING CANDIDATE 































 1 1    1       
AOAC fiber 
gm 
 1  1          
Vitamin B12 
mcg 
1   1    1     1 
Vitamin B1 
mg 
1             
Vitamin B2 
mg 
1      1  1     
Vitamin B6 
mg 








1  1   1 1  1  1  1 
Caffeine mg 
 1  1     1     
Calcium mg 1 
      1 1     
Copper mg 
             
Linoleic gm 
  1  1    1 1 1  1 
Linolenic 
fatty acid gm 
    1         
Arachadonic 
fatty acid gm 






















1             
Choline from 
Glycerophos






          1   
Potassium 
mg 




             
Lycopene 
mcg 
1  1    1 1   1   
Magnesium 
mg 
          1  1 
Manganese 
mg 
     1        
Monounsatu
rated fat gm 
   1    1    1  
Vitamin B3 
mg 




1       1      
Phospherou
s mg 




1   1 1    1    1 
Saturated fat 
gm 




    1         
Total Sugars 
gm 
 1  1 1 1  1    1  
Protein gm 1 
            
Vitamin E 
         1    
Vitamin C 
mg 
1      1   1 1  1 
Vitamin D IU 




1 1     1  1    1 
Zinc mg 
     1        
1 = nutrient was selected as a predictor of the metabolite in stepwise regression 
 
